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ABSTRACT 
 
 Patent ductus arteriosus (PDA) is a congenital cardiovascular defect in which a 
fetal connection between the aorta and pulmonary artery does not close spontaneously 
shortly after birth. This defect is the most common congenital cardiovascular abnormality 
found in canines and when left uncorrected can result in serious complications and even 
death. In the dog, PDA has been historically corrected via surgical ligation, however 
minimally invasive options, namely the Amplatz® Canine Ductal Occluder (ACDO), have 
become the preferential closure method when available. However, while effective, use of 
the ACDO can be limited by its relatively large delivery system size and cost. Thus, an 
alternative device that addresses these limitations is desired.  
Shape memory polymer (SMP) foams are a unique class of materials that have 
promising applications in the field of minimally invasive occlusion devices. A prototype 
nitinol foam cage (NFC) device designed using these materials and nitinol has been 
constructed to treat and occlude canine PDA. The first iteration of the NFC was evaluated 
using mechanical and in vitro experiments to assess its performance compared to that of a 
commercial ACDO. While the results were promising, with the prototypes showing lower 
radial pressure than the ACDO, and exhibiting limited migration in vitro, improving the 
stability and fit within the PDA geometry was desired. Design alterations to the nitinol 
frame and amount of foam used were implemented to address these concerns. Verification 
tests of this prototype, included fatigue, radial force, stability, and ease of deployment 
assessments. The prototypes exhibited promising initial fatigue characteristics, generated 
 iii 
 
lower wall tensions, and exhibited similar stability and delivery characteristics compared 
to the ACDO. The results showed promising potential that with minimal refinement, the 
prototype NFC could be used for canine PDA closure.  
A hydrogel clot mimic was designed for use with shape memory polymer foams 
to assess the performance of prototypes following foam occlusion without the 
complications of using blood. A polyacrylamide composition was selected in which the 
storage modulus of the hydrogel-clotted foam matched that of a blood-clotted foam. The 
utility of these materials was demonstrated in a verification test using the NFC which 
measured the force required to dislodge the prototype from the PDA with bare and 
hydrogel clotted foams. 
 
 
 
 
 iv 
 
DEDICATION 
 
This dissertation is dedicated to my mother and father who have constantly 
provided me with love, support, and guidance throughout grad school and my entire life. 
Thank you, I love you both. 
 
 
 
 
 v 
 
ACKNOWLEDGEMENTS 
 
I would like to thank my committee chair, Dr. Duncan Maitland for supporting and 
guiding me through grad school. Dr. Maitland provided a well-equipped and collaborative 
lab environment to conduct research. The access to rapid prototyping equipment was 
invaluable for iterating on device designs, and improved the end-product that I was able 
to deliver. I thank him for recognizing my potential and advising me to pursue a PhD after 
starting in his lab as a Master’s student. The opportunity to continue development of the 
PDA device to the point at which we could deliver these into animals has been a difficult, 
but exciting pursuit. I really appreciated his method of offering guidance and non-
restrictive leadership. This allowed me to explore more ideas and feel a greater sense of 
ownership and pride of the work that I completed. I feel that his guidance has made me a 
better engineer and inventor.  
I would like to thank my committee members, Dr. John C. Criscione, Dr. 
Balakrishna Haridas, and Dr. Matthew W. Miller for their help and guidance. Dr. 
Criscione provided assistance and advice regarding the radial force analysis of the devices, 
and his knowledge of mechanics greatly strengthened that experiment and segment of my 
dissertation. Dr. Matthew W. Miller originally pitched this project to Dr. Maitland, and 
provided initial input, recommendations, and testing on prototype design. Thank you for 
providing me with an ACDO and catheters I could use to evaluate and test my prototypes 
against. I greatly appreciate your expertise and help. Dr. Haridas increased my knowledge 
of medical device design and development. 
 vi 
 
Thank you to Dr. Sonya Gordon, Dr. Ashley Saunders, Scott Birch and the Texas 
A&M Veterinary Cardiology team. Their constructive input regarding the prototype and 
knowledge of PDA procedures was valuable to further development of the design. I have 
always enjoyed working with this group on this project and in other endeavors.  
Thank you to all my friends and colleagues for their help designing and assisting 
with experiments and helping get through tough parts of grad school. The collaborative 
nature of everyone in the Biomedical Device Laboratory was instrumental in my 
development as an engineer. Thank you, Dr. Tony Boyle, Dr. Landon Nash, Dr. Todd 
Landsman, Dr. Andrew Weems, John Horn, Dr. Marziya Hasan, Dr. Wonjun Hwang, 
Jason Szafron, Jesse Bryant, Rachael Muschalek, Scott Herting, Grace Fletcher, and 
Bradley Due, for your advice, help with experiments, and support. I would especially like 
to thank Sarah Raines for her assistance performing the radial and dislocation force 
measurements of the devices. Her self-sufficiency, hard work, and dedication conducting 
those experiments was a tremendous help. Whether it was discussing the design of a 
project or winding down on a Friday night, each one of you made grad school and 
obtaining my PhD a better experience. 
I would like to thank my parents, Roy and Karen Wierzbicki, as well as my sisters, 
Dana and Kate Wierzbicki, for their constant encouragement and support throughout my 
entire academic career. Grad school has been a difficult journey, and I couldn’t have done 
it without you. I love you all.  
  
 vii 
 
CONTRIBUTORS AND FUNDING SOURCES 
 
Contributors 
 This work was supported by a dissertation committee consisting of Professors 
Duncan Maitland, John Criscione, and Balakrishna Haridas of the Biomedical Engineering 
Department and Dr. Matthew W. Miller of the Texas Institute of Preclinical Studies. 
Professor John Criscione was a valuable collaborator in analysis techniques and 
design of the radial force measurements in Chapter 4. Dr. Miller of the Texas Institute of 
Preclinical Studies provided valuable input in the design and requirements for the device. 
Additionally, he conducted the physiological in vitro deliveries in Chapter 2. Dr. Sonya 
Gordon of the Small Animal Clinical Sciences of Veterinary Medicine and Biomedical 
Sciences Department performed the physiological in vitro delivery experiments in Chapter 
4, and provided valuable input on prototype performance. Dr. Ashley Saunders of the 
Small Animal Clinical Sciences of Veterinary Medicine and Biomedical Sciences 
Department and Scott Birch of The Center for Educational Technologies provided the 
physiological morphology CT datasets used to construct the silicone models used in 
Chapter 4. Professor Jefferey Raymond of the Department of Chemistry and Andrew 
Weems of the Department of Biomedical Engineering assisted in the method development 
and execution and evaluation of the DMA foam measurements in Chapter 3, respectively. 
Sarah Raines of the Electrical Engineering Department was a valuable collaborator 
throughout the completion of Chapters 3 & 4. She performed the dislocation and radial 
force measurements in Chapters 3 &4. Jesse Bryant of the Biomedical Engineering 
 viii 
 
Department conducted the removal force measurements in Chapter 2. Brandis Keller of 
the Biomedical Engineering Department collected scanning electron micrographs of the 
prototypes described in Chapter 4. Landon Nash of the Biomedical Engineering 
Department assisted in the development of the strut integrity testing protocol described in 
Chapter 4. Bradley Due of the Biomedical Engineering Department was a collaborator 
throughout the initial stages of Chapters 3 & 4. All other work conducted for the 
dissertation was completed by the student independently. 
 
Funding Sources 
This work was made possible in part by the National Institutes of Health/National 
Institute of Biomedical Imaging and Bioengineering Grant R01EB000462 and National 
Institutes of Health/National Institute of Neurological Disorders and Stroke Grant 
NS0899692. 
  
 ix 
 
NOMENCLATURE 
 
Abbreviations:  
PDA: Patent Ductus Arteriosus  
MPA: Main Pulmonary Artery 
MDD: Minimal Ductal Diameter 
ACDO: Amplatz® Canine Ductal Occluder 
ADO: AmplatzerTM Duct Occluder 
AVP: AmplatzerTM Vascular Plug 
SMP: Shape Memory Polymer 
Tg: Glass Transition Temperature 
DA: Ductus Arteriosus 
ID: Inner Diameter 
OD: Outer Diameter 
NFC: Nitinol Foam Cage 
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WA: Wide Ampulla 
PDMS: Polydimethylsiloxane 
CTA: Computed tomographic angiogram 
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TRF: Total Radial Force 
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TEA: Triethanolamine 
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SPC: Small Pore Clot 
LPC: Large Pore Clot 
Bis: Bis-acrylamide 
SPH: Small Pore Hydrogel 
LPH: Large Pore Hydrogel 
ANOVA: Analysis of Variance 
NFCTn: Thin walled NFC 
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NFCTkEP: Thick walled, Electropolished NFC 
SACDO: ACDO Contact Pressure 
sTn: NFCTn Strut Force 
sTk: NFCTk Strut Force 
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BACDO: ACDO Blockwise Pressure 
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τTk: NFCTk Wall Tension 
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CHAPTER I 
INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Characteristics of Canine Patent Ductus Arteriosus  
 Patent ductus arteriosus (PDA) is a congenital cardiovascular defect in which a 
normal fetal connection between the aorta and main pulmonary artery (MPA) does not 
close shortly after birth. This connection between the arteries leads to continuous left-to-
right shunting of blood from the aorta to the MPA. The resulting overcirculation typically 
results in cardiac remodeling characterized by left ventricular and left atrial dilation with 
or without secondary mitral regurgitation. If uncorrected, the most common clinical 
outcome is left sided congestive heart failure or cardiogenic pulmonary edema and death 
[1, 2]. When left uncorrected, the one year mortality rate for this defect is reportedly 65% 
[3]. PDA accounts for 30% of all congenital defects found in dogs, making it the most 
common canine congenital heart defect [4].  
 PDA morphology is an important factor when determining the best closure method 
[5, 6]. It has been reported that morphology varies widely between dogs, and is not 
correlated with age or body weight [7]. Therefore, it is important to accurately measure 
the PDA dimensions prior to the procedure to ensure the best outcome. These 
measurements are usually carried out using angiography, transesophageal 
echocardiography, or both [8, 9]. Important factors to consider for device sizing include 
the minimal ductal diameter (MDD) and the ampulla shape, diameter, and length. The 
vessel between the aorta and MPA is known as the ductus, with the proximal (aortic side) 
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of the ductus being defined as the ampulla. The MDD is defined as the smallest diameter 
of the ductus as its connection to the MPA.  
An investigation of PDA in 246 dogs revealed four characteristic PDA 
morphologies as shown in Figure 1.1 [7]. Type I PDA is characterized as a narrow tube 
that gradually tapers, less than 15 degrees, from the aorta to the MPA. Type IIA PDA is 
initially tube like, then abruptly narrows prior to the MPA. This narrowing is greater than 
a 50% reduction in ductal diameter. Type IIB PDA exhibits a taper (between 30-60 
degrees), forming a conical shape, prior to an abrupt distal narrowing prior to MPA 
insertion. Type III PDA is tube-like with a relatively constant diameter (<20% ductal 
diameter reduction) [7].  
 
 
 
 
Figure 1.1: Typical PDA shapes. IIA and IIB are the most prevalent. Adapted from 
Miller et al [7]. Used with permission from Elsevier. 
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Type IIA PDA is the most common morphology, followed by Type IIB. Type III 
PDA is the least common morphology. Because it is usually larger in diameter than the 
other types, and the tube shape exhibits little taper (large MDD) to aid in securing a closure 
device, this type is usually treated via surgical ligation rather than through endovascular 
methods [7, 10]. 
 In addition to identifying the PDA morphology, the PDA size greatly influences 
decisions related to method of closure [8, 9, 11]. Dimensions of interest include the MDD 
and the ampulla length and width. These dimensions are labeled in Figure 1.2 as A, B, and 
C respectively [8]. MDD dimensions (A) range from 1-9.5mm [7] but are more commonly 
seen between 2.2-3mm [7, 8]. Typical ampulla lengths (B) and widths (C) are 9 mm and 
6-8 mm respectively [8, 12]. 
An important design consideration is the ability of the device to remain in position 
after deployment in the face of the large pressure gradient across the ductus from aorta to 
MPA. Physiological pressure gradients across the ductus have been measured using 
Doppler echocardiography as 80-140mmHg in conscious dogs [5, 13]. Following 
occlusion, the pressure gradient increases acutely and can exceed 200mmHg resulting in 
a reflex bradycardia, called the Branham reflex [14].  
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Figure 1.2: Typical PDA structures and dimensional measurements. A: Minimal 
ductal diameter (MDD). B: Ampulla length. C: Ampulla width [8]. Used with 
permission from John Wiley and Sons.  
 
 
 
 Following the procedure, there are multiple metrics used to determine success, 
chief being eliminating ductal flow (complete occlusion) or reducing residual flow to a 
hemodynamically insignificant volume. Occlusion is assessed 5-10 minutes immediately 
following deployment of the device via angiography and or transesophageal 
echocardiography. Additionally, an increase in diastolic blood pressure immediately 
following occlusion and the disappearance of pre-procedural continuous heart murmur 
indicates success. Finally, transthoracic echocardiography measurements to assess heart 
size and residual flow are performed at approximately 24 hours and six months post 
procedure. In rare cases, residual flow persists or develops at the 3-6 months 
reexamination, and if hemodynamically significant, can result in the need for a second 
procedure. [5, 15]. 
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1.2 Current Devices and Treatment History 
 Historically, surgical ligation of the PDA via thoracotomy has been an effective 
method of PDA closure [1, 6]. However, PDA surgery suffers from the expected morbidity 
associated with a thoracotomy with a reported mortality rate of  0-11%[3, 16], and the risk 
of major non-lethal complications such as hemorrhage, pneumothorax, and chylothorax is 
11-15% [16-19]. However, more recent publications suggest the mortality risk with 
surgical PDA ligation is on the lower side of the reported range, on average. Due to 
necessary morbidity and possible mortality, as in humans, in the dog, a viable minimally 
invasive treatment method is desired when available.  
The first intravascular closure of PDA in the dog was reported in 1994 [20], and 
since this time, many studies have reported the viability of catheter delivered devices 
intended for PDA treatment in humans and canines [1, 11, 19, 21-26]. Transcatheter 
methods were initially investigated to reduce surgical trauma, and complications, as well 
as cost [6]. Current endovascular treatments include embolization coils, devices used to 
treat PDA in humans, and the Amplatz® Canine Ductal Occluder (ACDO). 
 
1.2.1 Embolization Coils 
 Transcatheter embolization of PDA using embolic coils was the first commonly 
used endovascular closure technique of canine PDA [20]. Typical embolization coils 
(Figure 1.3) used for treatment include Gianturco or MReye® Flipper Detachable 
Embolization coils (Cook Medical) which are composed of surgical stainless steel coil 
windings and intertwined poly-Dacron fibers to enhance embolization [9, 11].  
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Figure 1.3: Fibered embolization coils intended for peripheral embolization in 
humans [9]. Used with permission from Elsevier.  
 
 
 
 Embolic coils are delivered either transarterially or transvenously [5] through a 4 
or 6 Fr catheter [9]. To position the coils using the transarterial method, 1-1.5 coil loops 
are deployed into the pulmonary artery and the remaining coil is delivered within the 
ampulla [9, 11, 27], or the entire coil is delivered within the ampulla [5, 24]. To position 
the coils transvenously, most of the coil is deposited in the ampulla and 1-2 loops cross 
the MDD into the MPA [28, 29]. There are two methods used to release these coils during 
deployment: controlled release and free push. Controlled release coils allow for retraction 
of the device for repositioning or removal prior to release [9]. Examples of controlled 
release methods include a threaded release from the delivery cable and an interlocking 
release wire [25]. Free push coils are deployed by pushing the coil out of the catheter using 
a guidewire. There is reduced control with the free push coils due to the inability to retract 
the device, however, procedures can be carried out in smaller catheters compared to 
control release methods, allowing for the treatment of PDA in small dogs [9].  
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 Three factors are considered when selecting the coil for treatment: coil wire gauge, 
coil loop diameter, and coil length. Embolic coils are available in various coil gauges 
(0.025”, 0.038”, 0.052”) and are used at different points during the procedure. It is 
recommended that the largest coil gauge that can pass through the catheter which has at 
least three revolutions when deployed be used for the initial coil [30]. This is followed by 
coils in a variety of diameters to seal leaks due to incomplete closure from previous coils. 
Smaller gauge coils are more compliant and better conform to the ductus [9]. The initial 
coil loop diameter used to occlude the ductus is usually chosen to be twice the diameter 
of the MDD and slightly larger than the ampulla width to secure the device in the ductus, 
followed by smaller sizes as needed [9]. Finally, the coil length determines the number of 
coils that can be used following complete deployment. A minimum of four loops is 
optimal for filling, and two to three coils are usually required to achieve complete 
occlusion in most dogs. An angiogram is recorded five to ten minutes after each coil 
delivered to assess residual ductal flow and the need to insert subsequent coils [9]. 
 Immediately after completion of the procedure, 36-77% [5, 31] of dogs showed 
residual flow, however 85% of these cases resulted in complete occlusion upon follow-up 
at 3 months [11, 24, 31]. Less than 5% of those that did not show complete occlusion at 
follow up required a second procedure [9].  
 In addition to the positive outcomes, mortality rates of coil embolization 
procedures are low, 1%, compared to 3-8% during PDA surgical ligation [3, 16]. Other 
complications include coil migration and embolization to the lungs, which has been 
reported to occur in 13-22% of cases [5, 24]. Retrieval of these coils is not typically 
 8 
 
attempted [11, 24] because adverse events have not been reported due the embolization of 
one or more coils [11, 24, 32]. However, coils cannot be used to close all PDA sizes and 
morphologies. As with all endovascular techniques, the PDA must taper sufficiently. 
Thus, the tube shaped (Type III) PDAs are not amenable to coil embolization because it 
does not adequately support the coils [9].  
 
1.2.2 Devices for Humans (Amplatz® Ductal Occluder and Amplatz® Vascular Plug) 
 To simplify procedures and improve procedural outcomes compared to coils, 
devices intended for occlusion of human PDA have been investigated for use in dogs. 
These devices used to occlude PDA and vascular defects in humans were investigated to 
treat large PDAs, not amenable to coil embolization, and to achieve a more consistent 
occlusion [2, 5, 21, 22, 25]. Additionally, these devices are easier to deploy, reposition, 
and typically require less procedural time when compared to coils [2]. The two main 
devices investigated were the AmplatzerTM Ductal Occluder (ADO) (St. Jude Medical, St. 
Paul, MN) and the AmplatzerTM Vascular Plug (AVP) (St. Jude Medical, St. Paul, MN). 
The ADO (Figure 1.4, left) is designed to treat human PDA and the AVP (Figure 1.4, 
right) is used for correcting peripheral vascular defects in humans. The ADO consists of 
a nitinol frame with polyester fabric sutured to the frame to aid in occlusion. The AVP 
consists of a dense nitinol wire mesh which slows blood flow, resulting in occlusion. 
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Figure 1.4: AmplatzerTM ductal occluder (ADO), left. AmplatzerTM vascular plug 
(AVP), right. The ADO is indicated for human PDA closure and the AVP is indicated 
for human peripheral embolization [6]. Used with permission from Elsevier.  
 
 
 
 The ADO was designed specifically for transvenous deployment, the preferred 
approach in humans. It is delivered using a 5-7 Fr sheath [21, 22, 25]. The device is 
advanced through the femoral vein to the pulmonary artery, through the ductus, and into 
the aorta. The device is advanced until the distal retention disk is deployed. The retention 
disk is then pulled to lie against the aortic wall and then the sheath is then retracted to 
deploy the rest of the device within the ductus [21, 22]. After positioning of the device, 
the clinicians wait approximately 10-15 minutes to assess ductal occlusion. If occlusion is 
deemed satisfactory, the device is detached from the delivery cable via threaded release, 
and the delivery cable is retracted [22]. 
 The AVP can be delivered transarterially or transvenously (transarterially is 
preferred in the dog) and requires a 4-6 Fr sheath, depending on the device size chosen to 
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occlude the PDA [2, 5, 25, 29]. The AVP is delivered within the ampulla of the PDA. 
Once stable positioning and adequate occlusion is confirmed, the device is released in a 
similar method to the ADO [25]. 
 Two dimensions are considered when choosing the ADO device size, the retention 
disk outer diameter (OD) and the size of the plug [21, 22]. It is recommended that the 
retention disk be 20-30% larger than the diameter of the ductus and that the diameter at 
the base of the plug be 2 mm larger than the MDD [21, 22]. The retention disk, and 
outward pressure exerted by the plug prevents the device from sliding through the ductus 
into the pulmonary artery. When treating PDA with the AVP, the plug diameter is selected 
such that it is 30%-50% larger than the ampulla diameter [2, 5, 25].  
 Closure with the ADO resulted in complete angiographic occlusion in 65% of dogs 
immediately following device deployment and release. Follow-up showed complete 
occlusion in 75% of dogs at 24 hours, 89% at three months, and 95% at one-year. All 
documented residual flow was minimal and hemodynamically insignificant. In addition, 
transductal flow did not reappear in the dog once the PDA was documented to be 
completely occluded [22]. However, one study reported less favorable results, reporting 
only a 55% successful occlusion rate [6]. 
 The occlusion outcomes of PDAs treated with the AVP were slightly less favorable 
than those treated with the ADO. Immediately post procedure, 47-50% were completely 
occluded [2, 5, 26]. Follow up at 24 hrs showed complete occlusion in 61-76% of cases, 
and 66% at three months [2, 5, 26]. 
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 Complications using the ADO included severe intra procedural arrhythmias, which 
could be due to the transvenous approach required for delivery of this device, necessitating 
the sheath be advanced through the right heart. Sission et al reported two deaths, which 
were believed to be a result of arrhythmias and atrial fibrillation [21, 22]. Complications 
were more prevalent when using the AVP compared to the ADO. When the ampulla 
dilates, shortly after occlusion, the AVP can begin to rotate and migrate from the desired 
position, greatly increasing the flow through the ductus [5, 25]. Additionally, while 
simpler to deliver than coils, disadvantages to this include the large sheath required to 
deliver this device. Many dogs cannot be treated due to inadequate femoral artery size.  
 
1.2.3 Amplatz® Canine Ductal Occluder (ACDO) 
 The Amplatz® Canine Ductal Occluder (ACDO) (Infiniti Medical, LLC, Menlo 
Park, CA) was specifically designed to treat canine PDA and conform to the canine PDA 
morphology [33]. Like the AVP and ADO, this device utilizes a dense self-expanding 
nitinol mesh to occlude the ductus [33]. This device was specifically developed by 
Nguyenba et al in conjunction with a company to address issues associated with other 
catheter treatment methods, such as, ease of deployment, device migration, and 
completeness of occlusion [1, 33]. The device, shown in Figure 1.5 consists of a distal 
disk, used for positioning against the MPA ostium, within the MPA, a narrow portion 
(waist) which is placed across the MDD, and a proximal disk that is deployed within the 
PDA ampulla that helps stabilize the device within the PDA.  
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 The ACDO is delivered transarterially, from the femoral artery, using either a 4-9 
Fr sheath, or 6-9 Fr guiding catheter [33]. It has been reported that dogs greater than 3 kg 
can be treated with this device (4 Fr sheath) [33]. When delivering the device, the ACDO 
is advanced through the sheath/catheter to the MPA, the device is advanced out of the 
catheter until the distal disk is protrudes into the MPA. The device and catheter are then 
retracted until the disk contacts the MPA ostium of the ductus. The sheath is then retracted, 
while holding the delivery wire stable, to fully unsheath the ACDO. The PDA is then 
inspected for adequate occlusion prior to release, and if deemed acceptable, the delivery 
cable is rotated counter-clockwise, and the device is released from the delivery wire [33].  
 
 
 
 
Figure 1.5: Amplatz® canine ductal occluder (ACDO). The ACDO was specifically 
designed to conform to and occlude canine PDA. 
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 The ACDO is available in a variety of sizes with the waist diameter ranging from 
3-10 mm in 1 mm increments and in 12 and 14 mm. These allow for the treatment of many 
different PDA sizes. Sizing is determined by the MDD. The device size is selected such 
that the waist is 1.5-2.7x larger than the MDD, the recommended target is 2x MDD in 
most cases [1, 5, 15, 33].  
 Clinical studies have shown this device to be very effective at occluding PDA. 
Immediately post-procedure, 75%-94% have complete occlusion, and at 24 hours, 97-
100% of PDAs were fully occluded [1, 5, 15]. There was no evidence of the reappearance 
of ductal flow in any ductus demonstrated to be completely occluded (recanalization) at 
three months post procedure [1]. 
 Complication rates when using this device are low. Device related complications 
have been reported as 3-6% [1, 5, 15]. These complications were either due to user error 
[15], improper device sizing [1, 5], or device migration into the pulmonary artery, likely 
a consequence of the first two [1]. In the case of improper device sizing, the device was 
retracted into the sheath/catheter and removed and a second more appropriate sized 
(smaller or bigger as required) device was delivered successfully. A smaller device is 
selected if the deployed device doesn’t assume an acceptable shape and a larger device is 
selected if the push-pull test results in easy dislodgement into the MPA. In one study, there 
were no significant clinical complications that resulted in the devices that embolized in 
the pulmonary artery [1], however, antidotal persona commination with Drs. Miller and 
Gordon confirm that this is a rare complication and as with MPA coil embolization is often 
non-fatal and does not require retrieval [12].  
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1.2.4 Summary of PDA Occlusion Methods  
 All transvenous PDA occlusion methods in the dog described above have been 
determined safe to use and have an overall success rate (including some clinically 
insignificant residual flow in some dogs) of 92% [5]. However, when comparing occlusion 
devices, the ACDO performed the best, occluding 98-100% of dogs [1, 5, 15], followed 
by AVP (93-100%) [2, 5, 26], ADO (89-100%) [22], and coils (86-100%) [5, 11, 22, 24, 
28, 29]. It is recommended that different PDA morphologies and sizes may require 
different endovascular techniques and devices [7, 21]. Type III PDA is the most difficult 
to occlude using currently available devices due to the lack of taper at the pulmonic 
ostium. However, the ACDO has been reported to successfully occlude Type III 
morphologies in some dogs [1, 6]. The AVP and coils are not recommended for use in 
Type III PDAs and coils should not be used in PDAs with MDDs greater than 5 mm due 
to the higher risk of migration into the MPA [21], the ACDO has been successfully 
deployed in wide range of MDDs and a variety of morphologies, including Type III [1, 6]. 
Use of the ADO has been reported in older dogs with large ducti [6]. To date, there are no 
published guidelines for method (surgery versus device) or device selection in dogs with 
PDA, and as such, is based on clinician preferences, availability of experienced 
individuals (veterinary cardiologists and surgeons), and to some extent, cost and patient 
size. 
 It is important for the device to remain in position once deployed. Coil migration 
is relatively common and is reported to occur in 22% of cases [24], whereas this occurs in 
0-6% of cases when the PDA is treated with the ACDO [1, 5, 15]. Additionally, migration 
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has been reported with use of the AVP such that the AVP can become disengaged from 
the ampulla and migrate into the MPA after delivery [2].  
The ACDO, AVP and ADO all require relatively large delivery systems, ranging 
from 4-9 Fr sheaths. Additionally, the ADO delivery system has been reported to kink 
during delivery due to the sharp bends required for the transvenous delivery and has been 
assessed as a poor treatment method, especially for dogs under 5 kg [6]. While coils are 
not ideal or most reliable method to treat PDA, they still offer the smallest delivery system, 
down to 3 Fr catheter [23], and many dogs must be treated with coils due to this sizing 
constraint [5, 33].  
While historically less invasive than surgical closure, device closure procedures 
can cost as much or exceed the surgical ligation cost, making many of these procedures 
cost prohibitive to dog owners [10]. However, despite the high cost and large delivery 
system required, the ACDO has been shown to exhibit better occlusion, lower 
complication rates, and is becoming preferred over the other endovascular closure 
methods [5]. 
 
1.3 Device Improvements Using Shape Memory Polymers 
 Unlike the current devices used to treat PDA which use a dense nitinol wire mesh 
or coils with embolic fibers, we plan to utilize shape memory polymer (SMP) urethane 
foams to occlude the ductus. Shape memory polymers are a class of materials which can 
be deformed, set into a temporary configuration, and actuated via an external stimulus, 
such as heat, to recover their original configuration [34, 35]. When an SMP is heated above 
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its glass transition temperature (Tg), it enters its rubbery phase and can be easily deformed. 
Above Tg, the amorphous chains of the polymer can be elastically deformed reducing the 
entropy of the system. If the SMP is held in a deformed configuration and cooled below 
its Tg, the chains will be fixed in the deformed shape. When the SMP is heated above its 
Tg, the chains will relax to their original configuration and the polymer will regain the 
entropy lost during deformation [35].  
 Shape memory polymer foams hold excellent promise in the biomedical device 
field. The unique compression and recovery capabilities of the material make them 
amenable to endovascular device deliveries. Singhal et al. have presented ultra-low 
density SMP foams exhibiting 70x volume expansion and 97-98% shape recovery. 
Additionally, the foams exhibit sharp, tailorable Tg’s between 45-70°C, allowing the user 
to choose the best composition for their desired application [36]. The foams have also 
displayed excellent biocompatibility in vitro and in vivo [5, 37, 38]. Rodriguez et al. 
performed a study analyzing the ninety-day biocompatibility of SMP foams in pigs, which 
showed stable thrombosis and cell infiltration in the foam volume, and less inflammatory 
response compared to an FDA approved suture material, indicating excellent 
biocompatibility and healing [37, 38].  
The interesting properties of these foams have prompted investigation for use as 
potential embolic agents for endovascular occlusion [39, 40]. In contrast to the current 
devices which utilize a dense wire mesh to occlude flow, we plan to occlude the ductus 
using SMP foam. 
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1.4 PDA Design Criteria 
Our primary consultant for this device was Dr. Matthew W. Miller, a board 
certified veterinary cardiologist with the Texas A&M Institute for Preclinical Studies. 
Through our meetings and literature review, we’ve determined five criteria that must be 
considered to develop a competitive device: Retraction, occlusion, detachment, 
device/delivery size, and radiopacity. The design criteria are summarized in Table 1.1 
below. 
Device retraction is defined by the ability to retrieve a device from the PDA once 
fully advanced outside the catheter, when still attached to the delivery cable. Device 
reposition is defined as the ability to fully advance the device outside the catheter, retrieve 
the device into the catheter, and redeliver the device to the site at a more ideal position. 
The devices currently used to treat PDA are repositionable, excluding free push coils, 
therefore, our device must be at least retractable for the design to be competitive. However, 
it was advised that the device does not need to be repositionable. This is an attractive 
characteristic, but it is not required for the end device. 
The device must occlude the vessel and promote local clot formation to ensure that 
the PDA is blocked. Polyurethane shape memory polymer foams will be used to occlude 
the vessel as the foam has been shown previously to embolize and exhibit healing in vivo 
and in vitro [36-38]. The ACDO exhibits clotting in approximately ten minutes [15]. The 
proposed device should match this metric for easier device adoption. However, Dr. Miller 
advised that a fast clotting time is not an important factor, if the device remains in position 
while the clot is forming, and the clot is not needed to hold the device in position.  
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The device will require a simple to operate, inexpensive to manufacture, 
detachment mechanism to release the device from the delivery wire. The ACDO utilizes 
a microscrew mechanism to detach from the delivery wire.  
To maximize the number of animals that can be treated with this device, the 
prototype must be deliverable through a 4 Fr sheath or smaller. This sized sheath can be 
properly positioned in most dogs with PDA. Using any catheters or sheaths larger than 4 
Fr removes a subset of dogs that can be treated with the device as it will not fit through 
the femoral artery. Delivery within a 4Fr catheter would be ideal, but is not required. 
Finally, the device must be radiopaque and visible under fluoroscopy to facilitate 
optimal positioning by the physician. 
 
 
 
Table 1.1: Summary of design requirements. 
Design Criteria Design Requirement 
Device Retraction 
Reposition 
Must be retractable. Does not have to be repositionable 
Must be retractable or not a viable option 
Occlusion 
Does not have to occlude immediately, but device must 
remain in position 
Detachment Should have a simple, inexpensive detachment mechanism 
Delivery Mechanism 
Most PDA’s accessible with 4Fr sheath 
4Fr catheter would be ideal, but not required 
Radiopacity Must be visible under fluoroscopy 
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CHAPTER II  
MECHANICAL AND IN VITRO EVALUATION OF AN EXPERIMENTAL CANINE 
PATENT DUCTUS ARTERIOSUS OCCLUSION DEVICE* 
 
2.1 Introduction 
The ductus arteriosus (DA) is a normal fetal connection between the aorta and 
main pulmonary artery (MPA). During the fetal development, the function of the DA is to 
shunt blood flow around the developing, but uninflated lungs. It remains open during 
development due to low oxygen tension [41] and the circulation of vasodilators [42-44]. 
After birth, oxygen tension greatly increases and the production of vasodilators decreases, 
causing the DA to constrict and close [45, 46]. 
However, in some cases, the DA does not close, resulting in a condition known as 
patent ductus arteriosus (PDA). The residual communication between the two arteries 
leads to continuous left-to-right shunting of blood between the descending aorta to the 
MPA. This loading can result in substantive cardiac remodeling and numerous clinical 
manifestations including cardiac arrhythmias, congestive heart failure, ventricular 
dilation, mitral valve regurgitation, pulmonary over-circulation, and death [1, 2]. This 
defect affects 6.8 in 1000 canine births accounting for 28% of all congenital cardiac 
malformations, making it the most common congenital cardiac defect found in dogs [4]. 
                                                 
* Reprinted from Journal of the Mechanical Behavior of Biomedical Materials, Vol 59, MA Wierzbicki, J 
Bryant, MW Miller, B Keller, DJ Maitland, “Mechanical and in vitro evaluation of an experimental canine 
patent ductus arteriosus occlusion device,” pgs 156-167, Copyright 2016, with permission from Elsevier. 
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When left uncorrected, the one-year mortality rate for this defect is 65% [3], necessitating 
closure.  
Traditionally, surgical ligation of the PDA via thoracotomy has been the accepted 
treatment for PDA in canines [1, 3, 47, 48]. However, this highly invasive surgery results 
in operative mortality rates from 0-11% [3, 16-19, 47] and risks of major complications 
such as nonfatal hemorrhage, pneumothorax, and chylothorax are 11-15% [16-19], 
increases the appeal of a viable minimally invasive treatment method [6]. 
The first intravascular treatment of PDA in the dog was reported in 1994 [20]. 
Since this initial report there have been studies investigating the viability of treating canine 
PDA with endovascular delivered occlusion devices intended for human use, such as 
embolization coils, the AmplatzerTM Vascular Plug (AVP), and the AmplatzerTM Ductal 
Occluder (ADO).  While these had varying success, there were still issues present such as, 
completeness of occlusion, device migration, delivery system size, and ease of delivery 
[2, 5, 6, 9, 21, 22, 24, 25, 27]. 
The Amplatz® Canine Ductal Occluder (ACDO) (Infiniti Medical, LLC, Menlo 
Park, CA), designed to address limitations of other endovascular treatments, was the first 
device designed to specifically conform to the canine PDA morphology [1, 33] and is 
currently the most widely used device to close PDA in dogs. The device is a dense, self-
expanding nickel titanium (nitinol) mesh which consists of a distal disk, used for 
positioning against the MPA ostium, a narrow waist which is placed within the minimal 
ductal diameter (MDD), and a proximal, cupped disk that helps stabilize the device within 
the PDA [33]. Clinical studies have shown the ACDO to be very effective at occluding 
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PDA, with 70-75% showing complete occlusion acutely upon implantation and up to 97-
100% at 24hrs [1, 5, 15]. However, while effective, this device is very expensive and cost 
prohibitive to some dog owners, pushing the cost of transvascular occlusion to approach 
and even exceed the cost of surgical ligation. Additionally, the size of the delivery system 
necessary for large ACDO’s can reduce the number of patients that can be treated with 
this device [15]. Canine PDA size is not associated with age or body weight [7], therefore, 
a small dog (<4 kg) may have a large PDA that cannot be treated because of the large 
delivery system required [6]. Therefore, there is a clinical need to develop a device 
addressing these issues. 
 A prototype device which utilizes shape memory polymer (SMP) urethane foams 
has been developed for endovascular PDA treatment. Shape memory polymers are a class 
of material which can be heated above a characteristic glass transition temperature (Tg), 
deformed, cooled below the Tg setting it into a temporary shape, and actuated by 
increasing the polymer’s temperature above the Tg via an external stimulus, such as heat, 
to return to their original shape [35]. These materials have been proposed for several 
biomedical device applications including use as embolic agents for endovascular 
occlusion [39, 40]. The ability of the foam to be delivered, compressed, and actuated to 
its original volume lends itself well to endovascular device delivery. Singhal et al. have 
demonstrated ultra-low density SMP foams with up to 70x volume expansion, 97-98% 
shape recovery after multiple cycles, and sharp, tailorable transition temperatures between 
45-70°C [36]. In addition, the foams have shown excellent biocompatibility in vitro and 
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in vivo, exhibiting the recruitment of collagen and connective tissue to form stable scar 
tissue, as well as clot formation within two minutes[36-38, 49]. 
 The goal of the present research is to develop an effective prototype PDA 
occlusion device with an equal or lower profile delivery system and with a lower cost than 
the ACDO. Decreasing the delivery profile of both small and large devices will allow 
clinicians to treat a greater population of dogs using minimally invasive techniques. 
Secondly, as the ACDO has become cost prohibitive, we have attempted to minimize the 
cost through reduction of materials used.  
For the device to be successful, it must conform to multiple design requirements, 
including that the device must: be retractable back into the catheter/sheath after delivery, 
be deliverable through a 4Fr sheath with 1.3mm inner diameter (ID) or smaller, 
occlude/reduce flow through the PDA to hemodynamically insignificant levels [36, 50], 
remain stable and not migrate once placed into the PDA, and be visible under fluoroscopy. 
These criteria will be evaluated in multiple mechanical and in vitro studies, which include 
radial pressure and removal force measurements, device stability and flow reduction 
measurements at physiological and elevated pressure gradients, and delivery into a 
physiologically representative model under fluoroscopy. Additionally, the mechanical 
properties and characteristics of the prototype device were compared to the properties of 
the ACDO.  
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2.2 Methods 
 PDA occlusion prototypes were fabricated using a custom process and then 
evaluated with mechanical and in vitro benchtop studies. Experiments performed included 
measuring the radial pressure the devices imparted on the vessel wall, measuring the force 
required to remove the device once positioned within the ductus, and evaluating device 
stability when subjected to physiological and elevated pressure gradients in simplified and 
physiologically representative in vitro models. These methods enable evaluation of the 
efficacy of the current prototype and how to approach further development of this design. 
 
2.2.1 Device Fabrication 
A monolithic nitinol foam cage (NFC), composed of a self-expanding nitinol frame 
and an SMP foam, was manufactured by laser cutting slots into a thin walled nitinol tube 
(NDC Inc, Fremont, CA) using a 248nm excimer laser (Resonetics, Nashua, NH) 
outputting approximately 100mW of power. The part was then deburred using abrasive 
paper and sonicated in isopropyl alcohol, followed by a heat treatment process to set the 
shape.  
The shaping process is detailed in Figure 2.1. First, stainless steel (SS) collars are 
positioned over the struts to prevent fracture formation during strut expansion, and a gauge 
pin was placed within the lumen of the tube to keep the device axial during the 
compression process, shown in Figure 2.1A. A SS spacer was placed inside the 
unexpanded proximal struts to aid in the shaping of the rectangular geometry as shown in 
Figure 2.1B, and positioned onto the fixture. The device was compressed axially to expand 
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the proximal (Figure 2.1C) and distal cages (Figure 2.1D); an external frame restrained 
the proximal cage, setting its shape. The device and fixture was then heat treated at 550°C 
for seven minutes in a furnace and subsequently quenched in room temperature water.  
 
 
 
 
Figure 2.1: NFC shape setting procedure. A: Laser cut nitinol tubing with SS 
spacers positioned and gauge pin placed within lumen. B: Interior SS spacer 
positioned in proximal struts. C: Tube is compressed axially so proximal cage 
opens. D: Tube is compressed axially further to expand distal struts. 
 
 
 
After the frame was created, a threaded detachment SS tube and nitinol backbone 
wire were attached. The backbone, constructed using 0.010” nitinol wire (NDC Inc, 
Fremont, CA) welded to a SS hypotube, was laser welded to the lumen of the threaded 
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detachment tube using an iWeld 990 (LaserStar, Riverside, RI), and this assembly was 
laser welded within the proximal lumen of the nitinol device frame. 
The SMP foam composition used in these devices was the 0TM composition 
described and synthesized in a similar way to those reported by Singhal et al. (Singhal et 
al., 2013). These foams were chosen for their rapid expansion in water (~2min in 37°C 
water) [51] allowing for fast occlusion of the PDA ductus, similar to the occlusion times 
of the ACDO (5-20 minutes) [15, 36]. These foams were post processed following the 
protocol described by Hasan et al. [52]. Foam cylinders 6mm diameter and 4mm long 
were cut from the cleaned foams using surgical biopsy punches and crimped over 0.010” 
nitinol wire using a radial crimping head (Machine Solutions, Flagstaff, AZ) to a diameter 
less than the nitinol tube inner diameter (ID). The compressed foams were threaded from 
the nitinol wire onto the device backbone wire within the proximal cage. Figure 2.2 shows 
a comparison of the ACDO to the NFC. 
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Figure 2.2: PDA device comparison. A: 6 mm ACDO (sized at the device waist); B: 
NFC, foam compressed; C: NFC foam expanded. (Same scale across frames). 
 
 
 
2.2.2 Model Fabrication 
 Four different models were constructed for device testing based upon PDA 
geometric classification as described in Miller et al. [7]. These included three simplified 
models (IIA, IIB, and wide ampulla (WA) taper), and a physiologically representative 
model of canine PDA. The dimensions and shapes of the simplified models are shown in 
Figure 2.3 and are based upon published data reported in Miller et al. [7]. The IIA and IIB 
models emulate the most common types of canine PDA morphology, and the WA model, 
based upon the IIA taper, was used to evaluate device performance when the device struts 
did not contact the vessel wall due to ampulla, the portion of the ductus proximal to the 
MDD, expansion [2, 7, 8]. 
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Figure 2.3: Simplified PDA model geometries. Dimensions and shapes based upon 
common canine PDA shapes [7]. 
 
 
 
 Simplified PDA models were created by 3D printing the PDA geometries, casting 
polydimethylsiloxane (PDMS) around the 3D printed model, and dissolving the printed 
material, leaving the vessel geometry.  
The physiologically representative vessel geometry was modeled using a 
computed tomographic angiogram (CTA) of a canine PDA. The surfaces of the 
descending aorta and MPA were extracted and sectioned using a trial version of Amira 3D 
analysis software (FEI Visualization Sciences Group Burlington, MA). Because the CTA 
provided was an unusual morphology, the geometry was modified to resemble a more 
typical IIA taper. The extracted volume was then imported into Solidworks (Dassault 
Systemes, Waltham, MA) for further processing and manufactured in a similar manner to 
the simplified PDA models using PDMS.  
 
2.2.3 Radial Pressure 
Radial pressure applied to the vessel wall by the device was measured to ensure 
that the device would not impose severe vessel trauma or ampulla rupture. Experiments 
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were performed using an Instron 5965 Test Frame (Instron, Norwood, MA) and Blockwise 
RJA62 J-CrimpTM Radial Compression Station (Blockwise Engineering LLC, Tempe, 
AZ), as shown in Figures 2.4A and 2.4B. The Blockwise employs a linear relationship 
between the positions of the extension arm and the diameter of the compression station 
shown below as, 
∆𝐷 = 0.7374 ∙  ∆𝑥,     (2.1) 
where ΔD is the change in diameter and Δx is the change in vertical position, and between 
the measured load seen by the extension arm and the radial force exerted by the device as, 
𝑇𝑅𝐹 = 2.712 ∙ 𝐹,     (2.2) 
where TRF is the total radial force and F is the force measured by the load cell. The TRF 
can be converted to radial pressure using, 
 𝑃 =  
𝑇𝑅𝐹
𝑆𝑡𝑟𝑢𝑡 𝑆𝐴
,      (2.3) 
where Strut SA is the surface area of the struts in contact with the Blockwise. To estimate 
the surface area of the ACDO in contact with the vessel wall, the ACDO was placed on a 
uniaxial tensile tester and elongated such that the diameter of the elongated ACDO was 
approximately the same as the vessel diameter to be tested. Images were captured and 
length measurements were conducted using ImageJ software (NIH, Bethesda, Maryland). 
These measurements were then used to estimate the surface area. 
The radial pressure of the NFC and a 6mm ACDO (sized at the device waist) was 
measured at five different diameters, 3.3, 4, 5, 5.5, and 6mm, to simulate the device being 
deployed in different sized vessels. Prior to each run, the 50 N load cell was balanced. A 
baseline measurement was recorded for each diameter and was subtracted from each data 
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set. Force measurements were recorded at a rate of 10 Hz for 30 s. Three NFC devices 
were tested at each diameter, and each test was conducted at least three times for each 
device. A single ACDO was tested at least three times at each diameter. The distal 
cage/disk of the NFC devices and ACDO was constrained during each of these tests with 
a Teflon tube, (Figure 2.4C), allowing only the proximal cage to expand, because it would 
not exert force on vessel walls radially in vivo.  
 
 
 
 
Figure 2.4: Radial pressure testing setup. A: Blockwise RJA62 J-CrimpTM radial 
compression station attached to Instron test frame. B: Enlarged, front view of 
compression blades, set to 5 mm diameter, with NFC deployed. C: Side view 
schematic of deployed NFC within compression station showing constrained distal 
cage. 
 
 
 
The radial pressure exerted by the devices was compared to the estimated burst 
pressure of the PDA vessel calculated using, 
𝑃 =
2𝑠𝑡
𝑑0
,     (2.4) 
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where P is radial pressure, s is the ultimate material strength, t is wall thickness, and d0 is 
outer diameter of the vessel. From this method, the approximate burst pressure of the 
canine aorta was calculated as 200kPa (1500mmHg) [53, 54]. 
 
2.2.4  Removal Force 
Experiments measuring the removal force were carried out using an MTS Synergie 
400 tensile tester (MTS, Eden Prairie, MN). During experimentation, the devices were 
deployed into simplified PDA models and submerged within an isothermal water bath held 
at 37-38°C. The distal end of each device was attached to the MTS gripper and was 
extended at 2.5mm/min until it was pulled through the MDD. Force was recorded at a rate 
of 10Hz. Three NFC devices and an ACDO were tested in each simplified PDA geometry. 
To assess repeatability, each NFC device frame was tested using three different foams 
(each 6mm diameter x 4mm long) as the foam is removable from the nitinol frame. The 
ACDO device was tested in each geometry at least three times. The removal force was 
recorded as the force required to dislodge the device from its implanted position, such that 
the proximal cage/disk protruded into the MPA.  
  
2.2.5 Device Stability and Flow Reduction in Simplified in vitro Models 
 The goal of this test was to determine whether the NFC device could withstand 
physiological and elevated pressure gradients and the amount of device migration and 
flow reduction when positioned into the previously described simplified PDA models. 
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2.2.5.1 Flow Setup 
A flow system was constructed and a representative schematic is shown in Figure 
2.5. Pressure gauges were placed proximally and distally to the PDA models to allow for 
measurement of the pressure gradient across the device. A water bath was used to hold the 
flow loop at 38°C, emulating the canine body temperature [55]. To control the pressure 
gradient across the ductus, a Y connector was placed prior to the PDA and a bypass arm 
was added. By adjusting the flow rate of the pump, the pressure gradient across the device 
could be controlled. A hemostasis valve was used to introduce the delivery sheath into the 
flow loop to the model geometry. 
 
 
 
 
Figure 2.5: Schematic of flow loop used for in vitro testing. 
 
 
 
2.2.5.2 Device Preparation and Delivery 
NFC devices were prepared with compressed, 6mm wide, 4mm long foams prior 
to experimentation. NFC and ACDO devices were delivered through a 4Fr sheath (Cook 
Medical, Bloomington, IN). The sheath was advanced through the ductus and the device’s 
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distal cage was deployed under a no flow condition. The sheath was then retracted such 
that the distal cage was then in contact with the modeled pulmonic ostium of the ductus. 
The proximal cage was then unsheathed, deploying the device. After the device was fully 
advanced out of the sheath, the delivery cable was rotated counter-clockwise to unscrew 
the cable from the device. Following release, the sheath and delivery cable were retracted 
out of the flow loop and the foam was allowed to fully expand.  
 
2.2.5.3 Device Stability Tests 
 Once the device was positioned and foam expanded (~1-5mins), the pump was 
turned on and the flow rate was set such that the pressure gradient across the PDA was 
approximately 100mmHg (13.3kPa) corresponding to the typical physiological pressure 
gradient across the ductus [5, 13]. The flow rate was then held constant and images of 
the device and the pressure gradient were recorded every minute for five minutes. 
Following the test at 100mmHg, the flow rate from the PDA arm of the flow loop was 
measured. Following the flow measurement, the systemic flow rate was increased to 
obtain a pressure gradient across the ductus of approximately 300mmHg (40 kPa) to act 
as a safety factor, and the image and flow rate collection procedure described above was 
completed. After collection of the final flow rate, the device was removed and the un-
occluded flow rate was collected for the flow speed used at each pressure gradient. Three 
different NFC devices were used and subjected to these tests three times in each of the 
PDA models for a total of twenty-seven tests. One 6mm ACDO was tested three times in 
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each of the PDA models. The ACDO was only evaluated at the physiological pressure 
gradient. 
Following the tests, device migration was assessed by measuring the length the 
distal end of the device moved relative to the MPA wall at zero (baseline), five (100 
mmHg), and ten minutes (300 mmHg) by importing the collected images into ImageJ 
image analysis software. 
 
2.2.6 Physiological Model in vitro Experimental Setup 
 An in vitro test was conducted within the Texas Institute of Preclinical Studies 
(TIPS) facility at Texas A&M with the goal of obtaining clinician feedback regarding the 
ease of delivery/use of the NFC compared to the ACDO when deployed into a 
physiologically representative model under fluoroscopy. The primary tests that were 
conducted included evaluating device stability, retractability, and flow reduction.  
 
2.2.6.1 Device Preparation 
 Four NFC devices and a 6 mm ACDO device were used in this experiment. Table 
2.1 below describes the device variants used. 
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Table 2.1: Physiological in vitro device list. Specifications of devices used in the 
physiological in vitro tests. 
 
 
 
The 4.5 mm OD distal cage type NFC design was tested in the simplified in vitro 
studies, and the 6 mm OD distal cage design was a variation used to test its ease of delivery 
when positioning compared to the smaller distal cage devices. The different sized foams 
were tested to monitor how foam diameter influenced flow reduction. The tungsten-doped 
foam device was tested to evaluate visibility under fluoroscopy compared to the non-
radiopaque foams [37]. 
 
2.2.6.2 Device Delivery 
 The same flow loop used for device stability measurements in Section 2.5.1 was 
used for these tests. Devices (Table 2.1) were preloaded into polytetrafluoroethylene 
(PTFE) tube introducers and loaded through a check-flow valve at the end of the 4Fr 
sheath by a veterinary cardiologist (Dr. Matthew W. Miller) and advanced to the model 
geometry under fluoroscopic guidance. Devices were deployed in a similar manner as 
ID Device Variant Expanded Foam Diameter 
NFC 1 4.5mm OD distal cage 6mm foam 
NFC  2 4.5mm OD distal cage 8mm foam 
NFC  3 6mm OD distal cage 6mm foam 
NFC  4 4.5mm OD distal cage 
6mm tungsten-doped foam (Rodriguez et al., 
2012) 
ACDO N/A 6mm waist (designed to occlude 3mm MDD) 
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described in Section 2.5.2. Following deployment, the pressure gradient across the device 
was increased to 100mmHg (13.3 kPa) by increasing the systemic flow rate and 
radiographic contrast was injected into the flow loop to qualitatively assess flow reduction. 
Additionally, when NFC 4 was implanted, the pressure gradient was increased to 
200mmHg (26.7 kPa), which can occur acutely, and contrast was injected to evaluate flow 
reduction. 
 
2.2.6.3 Device Retraction 
 Device retraction was performed on NFC 3 by the physician by pulling on the 
delivery cable to recapture the delivered device into the sheath.  
 
2.3 Results  
2.3.1 Radial Pressure 
The average radial pressure exerted by each device at each diameter is shown in 
Figure 2.6. Radial pressure for the ACDO and NFC decreased as the ampulla diameter 
increased. The pressure exerted on the wall by the ACDO was approximately equal to that 
of the NFC at ampulla diameters smaller than 5mm, but was higher at ampulla diameters 
of 5.5 mm and 6 mm. The peak pressure exerted on the wall by the ACDO was 36kPa 
(270 mmHg). The peak pressure exerted by the NFC was 33 kPa (247 mmHg). All NFC 
and ACDO devices tested exerted pressures below the calculated canine aorta burst 
pressure of 200 kPa (1500 mmHg). 
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Figure 2.6: Average radial pressure. Average radial pressure of the NFC compared 
to the ACDO at each ampulla ID tested. 
 
 
 
2.3.2 Removal Force 
Figure 2.7 shows the average removal force of the NFC and ACDO devices in each 
of the three simplified PDA geometries tested. The average removal force of the ACDO 
was higher than that of the NFC across all geometries tested. The average removal force 
was lowest for both the NFC and ACDO in the IIB geometry. The removal force of the 
NFC in the wide ampulla model was similar to that of the IIA model.  
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Figure 2.7: Average removal force. Average removal force of the NFC and ACDO 
for each simplified vessel geometry. 
 
 
 
2.3.3 Simplified in vitro Testing 
2.3.3.1 Device Stability 
 Figure 2.8 shows representative images of the devices after deployment in the in 
vitro benchtop studies, after five minutes at 100mmHg, and after five minutes held at 
300mmHg. The average migration was measured and calculated at these time points and 
is shown in Table 2.2. There was additional migration after the pressure gradient was 
increased to 300mmHg. The ACDO did not exhibit observable migration in any models 
tested. 
The devices in the IIA taper exhibited the most axial migration (Figure 2.8A). The 
proximal cages would slide in the ampulla when subjected to physiological pressures 
before contacting the MDD taper. The devices would slightly rotate in the IIB model at 
the elevated pressure gradient as shown in Figure 2.8B. The devices remained in position 
relatively well at the 100mmHg pressure gradient (B.2), but would slip and the device 
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would slightly rotate at the 300mmHg pressure gradient (B.3). The lowest migration was 
seen in the wide ampulla model (Figure 2.8C). The struts were fully deployed and rested 
on the flat MDD taper. The devices remained in position in the ampulla without applying 
outward pressure to the vessel walls. 
 
 
 
 
Figure 2.8: Device stability in the IIA (A.1-A.3), IIB (B.1-B.3), and WA (C.1-C.3) 
models. Flow is from left to right. Images recorded after device subjected to labeled 
pressures for five minutes. 
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Table 2.2: Device migration summary. NFC migration at physiological and elevated 
pressure gradients for each model tested. 
 
 
 
 
 
 
 
 
2.3.3.2 Flow Reduction 
 Flow through the PDA arm was measured with and without a device present at the 
physiological and elevated pressure gradients. The percent reduction in flow for each 
pressure and model is shown below in Table 2.3. NFC flow reduction was similar across 
each model for a given pressure gradient. Flow was impeded to the greatest extent by the 
NFC in the IIA model at both the physiological and elevated pressure gradients. The 
ACDO exhibited negligible flow reduction. 
 
 
 
 
 
 
 
Model 
Morphology 
NFC Axial Migration (mm) 
100mmHg 300mmHg 
IIA 0.7 ± 0.3 1.1 ± 0.4 
IIB 0.1 ± 0.2 0.8 ± 0.2 
WA 0.6 ± 0.4 0.8 ± 0.4 
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Table 2.3: Device flow reduction summary. Percent reduction of flow at the 
physiological and elevated pressure gradients. 
Model 
Morphology 
NFC Flow Reduction 
ACDO Flow 
Reduction 
100mmHg 300mmHg 100mmHg 
IIA 60% ± 5% 83% ± 2% 1% ± 0.2% 
IIB 51% ± 7% 80% ± 5% 0.6% ± 0.06% 
WA 58% ± 5% 78% ± 4% 0.7% ± 0.6% 
 
 
 
 
2.3.4 Physiological Model in vitro Experimentation 
2.3.4.1 Device Deployment  
The NFC devices were delivered to the geometry without difficulty. Figure 2.9 
shows images from the deployment of NFC 1 (Table 2.1). Figure 2.9A shows the NFC 
being advanced through the catheter to the MPA, Figure 2.9B shows the distal cage 
deployed, Figure 2.9C shows the distal cage pulled against the pulmonic ostium, and 
Figure 2.9D shows the entire device deployed. The NFC conformed well to the ductus and 
remained securely in position, even when the delivery cable compressed the proximal cage 
during deployment and release. It was noted that the NFC was much easier to advance 
through the sheath compared to the ACDO.  
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NFC 3 was easier to deliver than NFCs 1 and 2, due to the larger distal cage. NFC 
4 showed improved visualization due to the use of the tungsten doped foam. The clinician 
could visualize the foam expansion as a reduction in contrast, as shown in Figure 2.10. 
 
 
 
 
Figure 2.9: NFC deployment (NFC 1) into physiological model under fluoroscopic 
guidance. A: NFC in catheter. B: Distal cage deployed from catheter. C: NFC 
placement against pulmonic ostium of model. D: Proximal cage delivered and device 
released. White arrow indicates distal cage during deployment and positioning. 
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Figure 2.10: Tungsten-doped foam visibility under fluoroscopic guidance during 
NFC 4 delivery. A: NFC in catheter. B: Proximal cage deployment, foam begins to 
expand. C: NFC deployed, foam expansion indicated by reduction in the 
radiographic contrast of foam. White arrow indicates foam location. 
 
 
 
2.3.4.2 Device Retraction 
 NFC retraction into the sheath was assessed using NFC 3 (Table 2.1). The device 
was deployed as previously described in Section 2.5.2 and after the foam was fully 
expanded, NFC retraction was attempted while at a physiological pressure gradient of 
100mmHg. The clinician successfully retracted the device into the 4Fr sheath by holding 
the sheath in place and pulling the device cable to recapture the device.  
 
2.3.4.3 Occlusion 
The post deployment angiograms of NFCs 1, 2, 4, and the ACDO (Table 2.1) were 
compared to assess completeness of occlusion. Since no blood was present, the foam could 
not completely occlude the ductus with thrombus formation, however, flow reduction was 
expected. Figure 2.11 shows images of the devices within the model during angiograms. 
The foam of NFC 1 (Figure 2.11C) did not show appreciable flow reduction as the 
angiogram appeared similar to the baseline angiogram. It appears that NFCs 2 and 4 
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provided the best occlusion as indicated by the amount of contrast present in the ampulla 
during the angiogram (Figure 2.11 D&F). The contrast was slowest to clear in Figure 
2.11F, when the pressure gradient was set to 200mmHg. The ACDO showed similar flow 
reduction to the small foam NFC as indicated by the lighter contrast (Figure 2.11 B&C); 
NFC’s with larger and denser foams show darker contrast on the side of contrast delivery 
(Figure 2.11 D-F). 
 
2.4. Discussion 
2.4.1 Radial Pressure 
The ACDO exerted a higher pressure than the NFC at all ampulla diameters tested 
except at 4mm. The ACDO exerted a higher pressure than the NFC because the OD of the 
ACDO was 11mm whereas the OD of the NFC was 6.3mm (Figure 2.6). Additionally, the 
ACDO pressure may be underestimated as the proximal cup shape and waist could not be 
fully deployed into our test system as it would be deployed in vivo. 
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Figure 2.11: Flow reduction comparison. Images were collected at the time when max 
contrast was present in ampulla as determined by visual inspection. A: Model 
without a device present to provide a baseline image. B: Model with the ACDO 
positioned. C & D: NFC devices with a 6 mm diameter and 8 mm diameter SMP 
foam respectively. E & F: NFC 4 subject to a 100 mmHg and 200 mmHg pressure 
gradient respectively. 
 
 
 
The devices were tested at a range of vessel sizes to determine how the pressure 
exerted on the wall changed as a function of vessel diameter to ensure that the pressure 
exerted by an oversized device placed into a small PDA would not burst the vessel. The 
NFC is designed to be deployed in a PDA with a 5.5 – 6mm ampulla, and an MDD of 
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3mm. At these diameters, the device exerts approximately 2-11kPa (15-80mmHg) of 
pressure, which is much lower than the pressure exerted by the ACDO (16-17kPa, 120-
128mmHg) and the calculated burst pressure of 200kPa (1500mmHg).  
As indicated by the wide ampulla migration studies, radial pressure may not 
directly correlate to device stability. The oversized device waist and ability for the device 
to catch on a ductal taper are more important factors when predicting stability. The ACDO 
has been used to treat tubular PDAs without a ductal taper, but caution is urged when 
treating this shape because stability only comes from oversizing the device relative to the 
PDA diameter [1]. The NFC was found to exert pressures much lower than the estimated 
vessel burst pressure and on the same order of magnitude as the ACDO (Figure 2.6), which 
indicates that the current NFC design minimizes vessel trauma and the risk of ampulla 
rupture due to deployment pressure.  
 
2.4.2 Removal Force 
 The removal force of the ACDO was approximately six times higher than that of 
the NFC in all models tested (Figure 2.7). The cupped proximal disk and oversized waist 
of the ACDO increased the device stability and force required to remove it from position, 
resulting in no visible migration of the device in the in vitro tests. Therefore, it was 
concluded that higher removal forces correspond to increased device stability and reduced 
migration. 
 The removal force of the NFC was underestimated as the experiment only 
evaluated the removal force of the device frame, even with the presence of foam in the 
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device. In the in vitro experiments, the flow compressed the foam against the struts, 
keeping them flat against the taper of the ampulla, helping the entire device remain in 
position. In the removal force experiment, flow was not present and the foam was not 
compressed against the NFC struts. The removal force was lowest in the IIB model 
because the angled taper of the rigid model did not allow the devices to fully expand; 
therefore, the struts were already partially collapsed. The removal force was highest in the 
WA model because the devices were allowed to fully expand, increasing the amount of 
force required to collapse the struts into the MDD. These experiments would be more 
representative of in vivo conditions if thin walled PDMS models were used instead of the 
rigid, thick walled models used.  
 
2.4.3 Simplified Model in vitro Experiments 
2.4.3.1 Device Stability 
 Device migration and rotation is not desirable, but it was promising that the 
proximal cage and foam were not forced through the ductus. There was only one instance 
in which the struts on the proximal cage partially compressed into the MDD, but the device 
was not completely forced into the MPA. However, while it is optimal to minimize device 
protrusion into the MPA, minimal device protrusion has not been reported to cause clinical 
complications [32]. The ACDO did not exhibit visible migration once positioned, as has 
been reported in multiple in vivo studies [1, 5].  
The NFC migration could be due to the rigid PDMS model and fabrication 
methods used. A thin walled model would more accurately mimic a compliant blood 
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vessel and allow the device to fully expand and remain anchored in place. While no 
migration is desired, these initial results are promising and can be improved with future 
designs by modifying the cage. Decreasing the distance between the proximal and distal 
cages would allow the proximal and distal cages to better compress the tissue around the 
MDD.  
 
2.4.3.2 Simplified Model Flow Reduction Experiments 
 The NFC reduced flow by approximately 50% at the physiological pressure 
gradient and approximately 80% at the elevated pressure gradient (Table 2.3). It was not 
expected that the device would achieve 100% occlusion in the absence of blood. The goal 
of the test was to ensure that flow was being impeded. It has been reported that when 
similar SMP foams have been placed within blood vessels, clotting and complete 
occlusion of the blood vessel occurs in approximately two minutes [49]. The NFC reduced 
flow to a much greater extent compared to the ACDO, which showed negligible reduction. 
ACDO flow reduction at 300mmHg could not be assessed as the device did not impede 
flow enough to allow our system to develop this pressure drop. Despite the negligible 
reduction of flow in water, the ACDO performs very well when implanted clinically [1, 
5, 15]. Therefore, as evidenced by the reduction of flow in water and results from 
Rodriguez et al, the NFC should rapidly occlude the defect on a similar or faster timescale 
compared to the ACDO (~5-20min) [5, 15]. 
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2.4.4 Physiological in vitro Experiments 
 The overall response regarding the NFC from the veterinary cardiologist was very 
positive. The veterinary cardiologist commented that the deployment of the NFC devices 
offered easy delivery and effortless advancement through the delivery sheath, and was 
much easier to advance and exhibited much less resistance than the ACDO. The 6 mm 
ACDO used in this test is designed to be deployed through a 5 Fr sheath, however, it was 
delivered through a 4Fr sheath per standard clinical use [33]. It is desirable to deliver the 
devices through smaller delivery sheaths because it expands the population of patients that 
can be treated [6, 22]. The delivery time of the NFC was similar to that of the ACDO, 
meaning that the patient and clinician would not be subjected to a larger radiation dose 
than the current method due to increased procedure time. All NFC devices were properly 
deployed. Like the ACDO devices, the NFC was easily recaptured into the delivery sheath 
when repositioning was attempted. Therefore, the device could be retracted if there was 
an undesirable placement in the clinic. The ACDO did not appear to occlude flow as well 
as the NFC as indicated by the lighter contrast (Figure 2.11B). However, none of the 
devices exhibited complete occlusion because the blood clotting capabilities were not 
present. 
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2.5 Conclusions 
 The ACDO is an effective device for canine PDA occlusion, however, its large 
delivery system and expense limits its use in the clinic. An option that is deliverable in an 
equal or lower profile system with similar mechanical and occlusion properties and lesser 
cost is desirable.   
 The NFC conformed to the proposed requirements, and performed similarly to the 
ACDO in our tests. One area in which it shows improvement is its scalable aspect. The 
NFC cage diameter can be adjusted by increasing the length of the laser cut slots, thereby 
altering its expanded diameter, making it capable of treating large and small PDAs through 
a 4Fr sheath. The compressed OD is limited to the OD of the nitinol tube or compressed 
SMP, whichever is larger. Some ACDOs are deliverable in sheaths this size, but not those 
used to treat larger geometries. Additionally, using a smaller OD nitinol tube may allow 
for the treatment of canine PDA through even smaller delivery systems such as 4Fr 
catheters (OD ~1.3mm), further expanding the population of patients that could be treated 
with the NFC.  
 The NFC was designed to minimize materials used with the goal of reducing the 
cost compared to the ACDO. The NFC frame is formed from 1.25” of 0.044” OD, 0.041” 
ID nitinol tubing, and the ACDO’s frame is composed of two or three 144, 0.0015” – 
0.003” nitinol wires [33]. The cost of the SMP foam is negligible. The NFC minimizes 
materials needed for stability and occlusion (monolithic nitinol frame and SMP foam), 
compared to the hundreds of wires required for the ACDO. However, while we have 
shown a reduction of materials used in fabrication, there are other factors that contribute 
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to device cost, such as manufacturing processes and preclinical testing costs that will be 
analyzed in future studies. 
 The current NFC design is dependent upon the ability for the device to fully expand 
rather than to apply pressure to the vessel wall, as it appeared most stable in the WA model. 
This is encouraging because even if there is ampulla enlargement post deployment, it 
should not compromise the treatment as can occur with other endovascular treatment 
methods [2], further reducing the risk of complications during treatment. 
 The presented results and the promising clinician feedback obtained indicate that 
with design refinement, the NFC device could be used to treat canine PDA.  
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CHAPTER III 
SHAPE MEMORY POLYMER FOAM CLOT MIMIC UTILIZING ACRYLAMIDE 
HYDROGELS 
 
3.1 Introduction 
Patent ductus arteriosus (PDA) is a congenital abnormality in which the ductus 
arteriosus, connecting the aorta to pulmonary artery, does not close shortly after birth. This 
defect results in continuous left to right shunting of blood, which can lead to serious 
complications when left uncorrected, such as ventricular dilation, cardiac arrhythmias, 
congestive heart failure, and even death [1, 2]. PDA is the most common congenital 
cardiac defect found in canines, occurring in 0.68% of live births, and accounting for 28% 
of all congenital cardiac abnormalities in dogs [4]. Canine PDA has historically been 
treated via surgical ligation, a highly invasive treatment in which the chest cavity is opened 
and the ductus arteriosus is tied off with sutures and excised. More recently, minimally 
invasive techniques have been developed in an attempt to reduce the operative risk and 
ease use [1, 33], with the most common device used being the Amplatz® Canine Ductal 
Occluder (ACDO). While the ACDO is effective at treating PDA, its high cost and large 
delivery profile limit its use, prompting development of an alternative device [56]. 
Shape memory polymers (SMP) hold promise in the field of minimally invasive 
embolic devices. Due to their thrombogenicity and favorable healing properties with 
minimal inflammation [38, 57], ultra-low density polyurethane SMP foams have been 
investigated for use in many different applications, including aneurysm occlusion [57, 58], 
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peripheral embolization [59], and PDA occlusion [56]. Functionally, SMPs are a unique 
class of materials that undergo shape change upon the application of an external stimulus 
[34]. In the case of the SMP foams discussed here, the materials are amorphous thermosets 
that are thermally stimulated around the glass transition temperature (Tg); the SMPs are 
synthesized in an original expanded foam shape, heated to above their Tg, mechanically 
deformed to a compressed shape, and cooled to lock in the compressed geometry. This 
secondary geometry is held until the temperature is raised above Tg and the foam recovers 
its original, expanded shape. [34, 35]. Water plasticization can be utilized to enable further 
control over SMP foam-based device storage and actuation. Namely, once the hydrogen 
bonds in the polyurethane network are interrupted by water molecules, the Tg is effectively 
lowered. Thus, SMP foams are designed to remain stable under dry conditions and actuate 
upon exposure to the water in blood at body temperature, upon which they expand and 
absorb blood. The foam induces thrombosis through the intrinsic clotting cascade, and 
thrombus forms throughout the foam matrix [59].  
Typically, foam prototypes are evaluated without the use of blood or thrombi [56, 
58, 59]. However, it is important to evaluate device mechanical properties and 
performance after clotting. To this end, polyacrylamide hydrogels were chosen as a clot 
mimic due to the ability to tailor their mechanical properties by simply varying the 
concentrations of the acrylamide and bis-acrylamide monomers [60]. Additionally, 
polyacrylamide hydrogel clot mimics were previously used to investigate clot capture 
performance of inferior vena cava filters [61-63]. In the current work, SMP foams were 
doped with varied compositions of polyacrylamide hydrogels in effort to match the 
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modulus of a blood-clotted foam in two different pore size ranges. The clot mimic foam 
was then incorporated into a prototype PDA device to gain an understanding of device 
properties after implantation and clotting has occurred. Here, we focused on characterizing 
PDA prototype dislocation force before and after clotting.  
Devices indicated to treat PDAs must withstand many forces, including a 100 mmHg 
pressure gradient across the ductus that can increase to 200 mmHg acutely [personal 
communication, Matthew W Miller]. Prototypes have been tested at these pressures, but a 
second measure of stability is the force required to push the device through the minimal 
ductal diameter (MDD) after deployment in the PDA. This dislocation force measures 
device stability within the PDA and provides a comparative measure of frame stability 
across different device types. It was hypothesized that dislocation force increases after 
foam clotting, in turn decreasing the likelihood of device migration, which could occur 
due to ampulla enlargement or acute pressure increases. Frame stability during device 
placement is another important design consideration. When implanting these devices, 
clinicians push and pull the delivery cable after positioning the device to ensure that the 
device is stable [15]. If the dislocation force is excessively low, the devices get pushed 
through the PDA anatomy during positioning and cannot be confidently placed in the 
correct position. 
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3.2 Materials and Methods 
3.2.1 Materials 
N,N,N′,N′-tetrakis (2-hydroxypropyl)ethylenediamine (HPED) (99%; Sigma–
Aldrich), triethanolamine (TEA) (98%; Sigma–Aldrich), and hexamethylene diisocyanate 
(HDI, TCI America Inc., Portland, OR) were used to synthesize the SMP foams. 
Additional foaming components included surfactants, DC 198 and DC 5943 (Air Products 
and Chemicals, Inc., Allentown, PA), catalysts, T-131 and BL-22 (Air Products and 
Chemicals, Inc., Allentown, PA), and a physical blowing agent, Enovate 245fa 
(Honeywell International Inc, Morristown, NJ). Hydrogels were synthesized using 40% 
(w/v) acrylamide stock solution (Sigma-Aldrich), 2% (w/v) bis-acrylamide stock solution 
(Sigma-Aldrich), tetramethylethylenediamine (TEMED) (Sigma-Aldrich), and 
ammonium persulfate (APS) (Sigma-Aldrich). The hydrogel stock solutions were stored 
at 4°C when not in use. 
 
3.2.2 Foam Preparation 
Foams were prepared following the three-part process described in Hasan et al 
[52]. Briefly, appropriate molar ratios of HDI, TEA, and HPED were reacted over two 
days to form an isocyanate (NCO) prepolymer. Then, a hydroxyl (OH) monomer mixture 
was prepared by mixing molar ratios of TEA, HPED, a small amount of deionized water, 
and catalysts. The NCO and OH mixtures were combined with surfactants and blowing 
agents, mixed, and poured into a foam bucket to react and cure. By tailoring the viscosity 
of the premixes, large (1970 ± 240 um transverse pore diameter) and small (650 ± 130 um 
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transverse pore diameter) pore foams were fabricated. Figure 3.1 shows images of the 
transverse and axial pores, and Table 3.1 displays the full pore size characterization of the 
foams used. Foam was sectioned into 7 x 6 x 3 cm blocks and reticulated following the 
method described previously [49]. The blocks were then conditioned by compressing and 
expanding them at 100°C. Cylinders with a diameter of one centimeter were punched out 
of the reticulated, conditioned block, cleaned through multiple sonication and tumble 
cycles in isopropyl alcohol and water, and freeze-dried to preserve their cylindrical 
geometry. Foam cylinders with diameters between 9.5 – 10 mm and heights between 6.6 
– 6.9 mm were cut from the freeze-dried cylinders for testing. 
 
 
 
 
Figure 3.1: (A) Transverse and (B) axial pore images of (1) small and (2) large pore 
foams.  
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Table 3.1: Pore size characterization of small and large pore foams. Aspect ratio 
defined as the length of the pore in the foaming direction/length of pore in the radial 
direction.  
 
Transverse Pore 
Diameter 
Axial Pore Diameter 
Axial Pore 
Aspect Ratio Long Axis 
(Foaming 
Direction) 
Short Axis 
(Radial) 
Small Pore 
Foam 
650 ± 130 um 1310 ± 240 um 530 ± 100 um 2.5 ± 0.5 
Large Pore 
Foam 
1970 ± 240 um 1980 ± 400 um 1620 ± 190 um 1.2 ± 0.3 
 
 
 
For each pore size, three variants were tested in this study: bare, blood-clotted, and 
hydrogel-clotted foams (Figure 3.2). Bare foam refers to the clean SMP foam with no 
fillers. Small and large pore bare foams are denoted SPB and LPB, respectively.  
 
 
 
 
Figure 3.2: Top and side view of small and large pore bare, blood-clotted, and 
hydrogel-clotted foams. Foams displayed are 10 mm in diameter. 
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3.2.3 Blood-Clotted Foam Preparation 
Bovine blood was acquired from the Rosenthal Meat Science and Technology 
Center (Texas A&M University in College Station, TX) as a part of a tissue share program. 
The blood used in this study was collected from animals euthanized for purposes unrelated 
to this research. The blood was citrated in a 3.2% sodium citrate solution prepared in 
phosphate buffered saline (PBS). The citrated blood was stored at 4°C until use. Foam 
cylinders were plasticized in warm PBS, compressed to remove most of the saline, and 
placed in an acrylic well plate (1 cm diameter wells). Then, the citrate was counteracted 
using 10 mM calcium chloride [59]. Blood was deposited into each well, which caused 
the foams to expand. The foams were gently manipulated with tweezers while inside the 
well to minimize air bubbles and then allowed to fully expand. Following expansion, the 
plates were covered and incubated at 37°C for 2 hrs to clot the blood within and around 
the foams [61]. The blood-clotted foams were stored at 4°C and warmed up to room 
temperature for 24-48 hours prior to modulus measurements using dynamic mechanical 
analysis (DMA). Small and large pore blood-clotted foams are denoted SPC and LPC, 
respectively. 
 
3.2.4 Hydrogel-Clotted Foam Preparation 
Polyacrylamide clot mimics were fabricated following a protocol by Tse et al. [60]. 
Briefly, both acrylamide components were combined with water at the volumes designated 
in Table 3.2. All gels were fabricated with 3% acrylamide, and the bis-acrylamide (bis) 
concentration was varied to achieve the desired modulus. Then, 10% APS was added at a 
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1 vol% concentration, and TEMED was added at 0.1 vol%. The solution was vortexed and 
immediately deposited onto foams in 1 cm diameter well plates, as described above in 
Blood-Clotted Foam Preparation. Following foam expansion, the wells were covered and 
held at room temperature for 30 minutes to allow the hydrogel to crosslink. The hydrogel-
clotted foams were then removed from the wells and stored overnight in reverse osmosis 
water. Small and large pore hydrogel-clotted foams are denoted SPH and LPH, 
respectively. The hydrogel compositions used were selected based upon preliminary data 
which suggested that these monomer compositions would result in hydrogel-clotted foams 
with moduli that were approximately equal to the blood-clotted foam moduli. 
 
 
 
Table 3.2: Hydrogel compositions used for hydrogel-clotted foam preparation.  
 Gel Composition 40% 
Acrylamide 
Solution 
(mL) 
2% Bis-
Acrylamide 
Solution 
(mL) 
10% 
APS 
solution 
(mL) 
TEMED 
(mL) 
Water 
(mL) 
Acrylamide Bis-
Acrylamide 
Small 
Pore 
Foam 
3% 0.085% 0.75 0.425 0.1 0.01 8.825 
3% 0.080% 0.75 0.400 0.1 0.01 8.85 
3% 0.075% 0.75 0.375 0.1 0.01 8.875 
Large 
Pore 
Foam 
3% 0.045% 0.75 0.225 0.1 0.01 9.025 
3% 0.035% 0.75 0.175 0.1 0.01 9.075 
3% 0.0325% 0.75 0.1625 0.1 0.01 9.0875 
 
 
 
3.2.5 Dynamic Mechanical Analysis of Foam Samples 
Foams were tested using immersion clamps on a q800 DMA (TA Instruments, 
New Castle, DE). Samples were loaded into the compression clamps, and 37°C PBS was 
added to the base of the top compression plate. The storage and loss modulus were 
measured by performing a kinetic experiment [58, 64, 65] with the samples subjected to 
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1% strain at a frequency of 1 Hz. The oven temperature was ramped to 37°C, and the test 
was carried out for at least 45 minutes until the storage modulus plateaued. Six samples 
of each foam formulation were tested. 
3.2.6 Nitinol Foam Cage Prototype Fabrication and Preparation 
PDA prototypes, termed the nitinol foam cage (NFC), were fabricated similar to 
those described in Wierzbicki et al. [56]. Briefly, ten equally spaced radial slots were 
excimer laser cut (Resonetics, Nashua, NH) into straight nitinol tubing (NDC, Fremont, 
CA). Following deburring, the laser-cut tubes were secured in custom fixtures and 
compressed to conform to the desired frame geometry. The nitinol was shape-set at 550°C 
for 25 minutes followed by a water quench. The proximal and distal ends of the nitinol 
frame were then cut to length, and a threaded, stainless steel hypotube was affixed to the 
proximal end to allow for detachment of the device from the delivery rod. The monolithic 
frame consists of multiple distinct cages. The flat disc-like distal cage rests against the 
pulmonary artery wall and serves as a landmark during deployment for the clinician. The 
proximal cage serves as the anchor point for the SMP foam and applies an outward force 
to the ampulla to aid in device stability. The waist is a narrow portion between the 
proximal and distal cages that resides within the MDD. The waist is designed to be two 
times the diameter of the MDD and serves as the main stability mechanism for the NFC.  
  
3.2.7 PDA Model Fabrication 
The dislocation force of NFC prototypes and a commercial Amplatz® Canine 
Ductal Occluder (ACDO) were evaluated in simplified models of the most common types 
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of canine PDAs (Figure 3.3), including the cylindrical IIA, the conical IIB, and wide 
ampulla for cases in which the ampulla expands post occlusion [2, 7, 8]. Construction of 
the thin walled silicone models is detailed in previous work. The waist of the NFC and 
ACDO devices is designed to be two times oversized relative to the MDD of the PDA. To 
assess the influence of proper device sizing on the dislocation force, devices were 
deployed into two different diameter MDD models, 3 and 5 mm (2x and 1.2x oversized 
relative to the MDD). 
 
 
 
 
Figure 3.3: Simplified schematics of PDA models used in dislocation force testing.  
 
 
 
3.2.8 Dislocation Force Testing 
The dislocation force of a 6 mm waist ACDO was compared to that of 6 mm waist 
prototypes with bare and hydrogel-clotted small and large pore foams. The foams (8 mm 
diameter cylinders) were prepared as described in Foam Preparation. Hydrogel-clotted 
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foams were frozen at -20°C and freeze dried following polymerization. Once lyophilized, 
both bare and hydrogel-clotted foams were compressed in a heated stent crimper to a 
minimal diameter. Compressed foams were glued to the interior proximal end of the 
nitinol frame, and trimmed to the length of the cage. Figure 3.4A-E show the ACDO and 
NFC devices with compressed and expanded bare and hydrogel-clotted foams. Each 
device was loaded into a thin walled silicone model of a PDA geometry, with the distal 
cage placed within the modeled pulmonary artery, the waist placed within the MDD, and 
the proximal cage placed within the ampulla (schematic shown in Figure 3.4F) and placed 
in 50°C water for an appropriate amount of time to fully actuate the SMP foam. A threaded 
rod was attached to the proximal end of the NFC, and the model with the prototype was 
placed into a water bath (35-37°C) positioned on an Instron 5965 test frame (Instron, 
Norwood, MA) (Figure 3.4G). The rod, extending from the proximal end of the NFC, was 
secured to the Instron grip. The crosshead was lowered at a rate of 2 mm/min until the 
device was completely pushed through the minimal ductal diameter into the modeled 
pulmonary artery. The force was recorded throughout the test using Instron Bluehill® 3 
testing software, and the dislocation force was recorded as the maximal force recorded 
during the test. For each permutation, three devices were tested one to three times each.  
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Figure 3.4: Dislocation force testing summary. A: ACDO. B: NFC with compressed 
bare foam. C: NFC with expanded bare foam. D: NFC with compressed hydrogel-
clotted foam. E: NFC with expanded hydrogel-clotted foam. F: Schematic of proper 
NFC deployment in idealized IIA PDA geometry. G: Dislocation force setup with 
NFC loaded onto Instron prior to test start. A-E: Scale in mm. 
 
 
 
3.2.9 Statistical Analysis 
Two-sided analysis of variance (ANOVA) with Tukey multiple comparison 
analysis, comparing the mean of each sample with the mean of every other sample, was 
used to compare differences in storage moduli of small and large pore, bare, blood-clotted, 
and hydrogel-clotted foams. Dislocation force comparisons were analyzed using a two-
sided ANOVA with Tukey multiple comparison analysis. Two analyses were performed 
to assess multiple comparisons, one comparing dislocation force differences across foam 
types, and a second comparing dislocation forces across PDA models. In instances in 
which multiple measurements were recorded for the same prototype frame, the average 
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was first computed for the replicates and the final average and standard deviation was 
calculated from the averaged replicate measurements of each prototype. In all cases, 
significance was determined with a level of 95% (p<0.05). All statistics were performed 
using Graphpad Prism 7 (Graphpad Software, Inc, La Jolla, CA). 
 
3.3 Results and Discussion 
3.3.1 Dynamic Mechanical Analysis  
A series of bare, blood-clotted, and hydrogel-clotted foams were characterized at 
37°C to find a hydrogel clot mimic composition with comparable modulus to that of blood-
clotted foams. The resulting storage, loss, and complex moduli are shown in Table 3.3, 
and a comparison of storage moduli are displayed in Figure 3.5. The storage moduli of the 
bare small and large pore foams were not statistically different. Blood-clotted foams had 
increased storage moduli relative to bare foams, with a larger increase observed in the 
small pore blood-clotted foams. Statistical comparison of SPC and SPH formulations 
revealed that there were no significant differences (p<0.05) between the moduli of the 
SPC and that of any SPH formulation; however, modulus decreased with decreasing bis-
acrylamide concentration, following trends reported by Tse et al. [60]. A significant 
difference was observed between the 0.085% and 0.075% bis-acrylamide composition 
SPH foams. The increase in modulus between the LPB and LPC foams was not significant. 
Like the small pore foams, there were no significant differences between any of the LPC 
and LPH compositions, but there was the similar trend of decreasing moduli with 
decreasing bis-acrylamide concentration from 0.045% to 0.035%. The moduli of the 
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0.035% and 0.0325% compositions were relatively unchanged. As the means of the SPH 
with 0.08% bis-acrylamide and the LPH with 0.0325% bis-acrylamide most closely 
matched those of the SPC and LPC, respectively, these formulations were selected as the 
compositions for further studies (hereby simply designated as SPH and LPH).  
 
 
 
Table 3.3: Storage, loss, and complex moduli of all foam compositions. 
 Storage Modulus 
(kPa) 
Loss Modulus 
(kPa) 
Complex Modulus 
(kPa) 
Small pore bare 1.3 ± 0.7 0.5 ± 0.2 1.4 ± 0.7 
Small pore clot 4.3 ± 0.6 2.0 ± 0.5 4.8 ±0.6 
Small pore hydrogel 
0.085% bis 
5.1 ± 0.8 1.0 ± 0.2 5.2 ±0.8 
Small pore hydrogel 
0.080% bis 
4.5 ± 1.0 1.1 ± 0.3 4.6 ± 1.0 
Small pore hydrogel 
0.075% bis 
3.2 ± 0.8 1.1 ± 0.4 3.4 ±0.9 
    
Large pore bare 0.9 ± 0.5 0.5 ± 0.5 1.1 ± 0.4 
Large pore clot 1.7 ± 0.3 0.8 ± 0.4 1.8 ±0.4 
Large pore hydrogel 
0.045% bis 
2.5 ± 0.7 0.3 ±0.1 2.5 ± 0.7 
Large pore hydrogel 
0.035% bis 
1.9 ± 0.4 0.6 ±0.5 2.0 ± 0.4 
Large pore hydrogel 
0.0325% bis 
1.8 ± 0.3 0.4 ± 0.3 1.9 ± 0.3 
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Figure 3.5: Mean storage modulus of prepared foam compositions. SPB: Small pore 
bare; SPC: Small pore clot; SPH: Small pore hydrogel; LPB: Large pore bare, LPC: 
Large pore clot; LPH: Large pore hydrogel. All hydrogel-clotted foams made with 
3% acrylamide. Bis-acrylamide concentration noted below each respective column. 
 
 
 
We hypothesize that the shape of the pores in the foams influenced the modulus of 
the clotted foams, resulting in a larger increase in modulus after clotting the small pore 
foams. When a 1600 µm length of LP foam is compressed, there are two struts to resist 
compression (short axis axial pore size is 1620 µm). When clotted, there is material in the 
pore, but the struts are still able to bow out and are thus less resistant to compression. For 
the same length of foam in the small pore foams, there are three struts with clot filling the 
cells in between (short axis axial pore size is 530 µm). Thus, the outer struts would bow 
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out under compression, but the middle strut would be supported by the clot and be more 
resistant to buckling. The higher number of vertical struts in the small pore foam compared 
to that in the large pore provides a greater resistance to applied compression. The minimal 
difference in modulus between the SPB and LPB foams was not statistically significant 
and could be attributed to the lack of a physical constraint within individual pores, 
allowing for buckling of struts rather than reinforcement. Furthermore, the axial pores of 
the small pore foams are less isotropic compared to those of the large pore foams, with 
aspect ratios (length of pore in foaming direction/length of pore in radial direction) of 2.5 
± 0.5 and 1.2 ± 0.3 (Figure 3.1 B.1 and B.2; Table 3.1), respectively. The clots within the 
relatively columnar pores of the small pore foams better resist compression compared to 
the more spherical clots formed in the large pore foams. When compressed, the SPC foams 
have higher stiffness in their taller struts in addition to the constraint of the fibrin mesh in 
the pores. 
  
3.3.2 Dislocation Force  
Upon selection of suitable hydrogel compositions for the clot mimics, the 
dislocation forces were measured in an immersion chamber held at 35-37°C in each PDA 
model for all prototype device and foam compositions in comparison to the commercial 
ACDO, Figure 3.6. Overall, the ACDO exhibited a significantly higher dislocation force 
than all prototypes. There were minimal differences in the dislocation forces of the 
prototypes; however, the dislocation forces of prototypes containing small pore foam were 
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approximately equal to or slightly higher than that of prototypes containing large pore 
foams for each model, as was expected.  
In general, the 3 mm MDD models resulted in higher dislocation forces compared 
to the 5 mm MDD models, because each device was forced through a smaller orifice. This 
difference was significant for all foam types and ACDO devices in the IIA and IIB models 
(p<0.05), except for the LPH foams in the IIB models. The large standard deviation in the 
IIB 3 mm SPH prototypes is partly due to the setup. Namely, the diameter of the SPH was 
too large for deployment across the 3 mm MDD as shown in Figure 3.4F,G; therefore, the 
foam was deployed entirely in the ampulla. For all other prototypes, the foam was 
deployed across the MDD. In some runs with the SPH in the IIB 3 mm model, the cage 
was not forced through the MDD axially, and the pushing rod rubbed the side of the model, 
increasing variability and resulting in a higher standard deviation. The wide ampulla 
models resulted in similar dislocation forces for both the 3 and 5 mm MDD, with the 
largest decrease seen in the SPH samples, indicating that stability could be influenced by 
the ratio between the ampulla and minimal ductal diameter.  
It was expected that the dislocation force would increase between the bare and 
hydrogel-clotted foams; however, they were very similar in these tests, and there was not 
a significant difference between SPB and SPH or LPB and LPH prototypes for a given 
model. The minimal difference between bare and clotted foams is important, because it 
shows that the ability to resist dislocation is not negatively or positively impacted by 
clotting. However, we hypothesize that fibrin in the thrombus and mature connective 
tissue would better bind the foam to the vessel wall over time [38, 57], which could 
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increase the dislocation force in vivo. It should be noted that lyophilization, compression, 
and rehydration of the foam may alter the modulus from values presented in Dynamic 
Mechanical Analysis results. 
While the differences in dislocation forces are small, these experiments still 
provide important design considerations for embolic devices. Dislocation force is 
primarily dictated by the nitinol cage rather than other variables, such as foam pore size 
or clot presence. Although the dislocation force of the prototype is approximately three 
times lower than the ACDO, this result does not indicate that the prototypes will not 
withstand the necessary physiological pressures. Other in vitro stability tests analyzing 
migration have shown stability under relevant pressures [56]Wierzbicki 2017 in prep]. 
Dislocation force is also an important characteristic in user deployment. Following 
placement of PDA devices, clinicians apply a gentle ‘to and fro’ motion to ensure that the 
device is securely positioned [15]. During previous in vitro studies, a clinician noted that 
it was much easier to push the prototype through the MDD compared to the ACDO, 
indicating that increasing the dislocation force of the prototypes could be beneficial. Thus, 
future work will focus on increasing the dislocation force of the device while still 
maintaining the desirable properties relative to the ACDO. 
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Figure 3.6: Dislocation force of for each prototype/foam combination and the ACDO 
in each PDA model. 
 
 
 
3.4 Conclusions 
This study showed that the dislocation force is not significantly affected by the 
increased modulus of the foam after clotting. The rigidity of the nitinol frame is most 
influential on dislocation force and masks the effects of clotting within the foams. Foam 
pore size has a small effect on dislocation force. This result is partially because the foams 
are expanded across the MDD in ideal deployments. Thus, the foam does not have to be 
compressed through the MDD during dislocation. 
In addition to the dislocation force tests described here, these composite materials 
are useful for studying the stability and flow reduction of devices following occlusion. 
Wierzbicki et al. and Landsman et al. evaluated stability of two different prototype SMP 
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foam-based devices at physiological and elevated pressure and flows using bare foam 
devices. The bare foam increases resistance to flow, but does not completely occlude the 
vessel, which would occur physiologically once thrombus formed throughout the device 
[59]. Using a clotted foam device in a setup similar to that described previously [66, 67], 
which analyzes how the device restores normal flows and pressures following occlusion 
of the shunt, could be beneficial during prototype development to better predict in vivo 
behavior under controlled conditions. 
An additional advantage to using hydrogel-clotted materials is ease of handling. 
Acquiring, storing, and using whole blood greatly increases the difficulty and decreases 
the efficiency in which studies can be performed due to the added complications and 
preparation required. Hydrogel-clotted foams can be readily prepared with off-the-shelf 
hydrogel materials and integrated into study design without the added complications of 
biohazardous materials and blood handling to more rapidly screen device compositions. 
 A limitation to using these materials in in vitro tests is that the lyophilized hydrogel 
foam cannot be compressed to as small of a diameter as the bare foams that would be used 
in the actual application. Thus, the devices may have to be deployed through larger 
catheters for the experiment or manually positioned using a different method. While a 
limitation, hydrogel-clotted foam devices can still provide valuable information if they 
can be positioned correctly. Also, as the primary use of these materials is the evaluation 
of device performance post occlusion, deployment characteristics can be assessed on bare 
foams through separate benchtop studies. Overall, these studies provide (1) a platform 
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technique for consistent evaluation of the effects of clotting and (2) more information on 
a potentially valuable technology to treat PDAs.  
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CHAPTER IV 
AN EXPERIMENTAL CANINE PATENT DUCTUS ARTERIOSUS OCCLUDER 
BASED ON SHAPE MEMORY POLYMER FOAM IN A NITINOL CAGE 
 
4.1 Introduction 
Patent ductus arteriosus (PDA) occurs when a normal fetal connection between the 
aorta and pulmonary artery does not close shortly after birth, leading to a continuous left-
to-right side shunting of blood. When left uncorrected, the PDA leads to many 
complications including congestive heart failure and death [1, 2].  
PDA is the most common congenital cardiovascular defect that occurs in canines, 
manifesting in 6.8 out of 1000 live births and comprising approximately 28% of all 
congenital cardiovascular defects [4]. PDA has been traditionally treated via surgical 
ligation, in which the chest cavity of the dog is opened via thoracotomy and the ductus is 
ligated [1, 3, 47, 48]. While effective, surgical ligation is highly invasive, and carries non-
trivial operative risks including, nonfatal hemorrhage, pneumothorax, and chylothorax as 
reported in 11-15% of cases [16-19] and operative mortality in up to 11% of cases [3, 16-
19, 47], which increases the attractiveness for a minimally invasive closure techniques [6]. 
Many endovascular devices intended for human PDA and peripheral occlusion, 
such as embolization coils, the AmplatzerTM Duct Occluder (ADO), and the AmplatzerTM 
Vascular Plug (AVP), have been investigated as options to treat the canine PDA. While 
there has been some success using current human devices within the canine anatomy, 
complications such as completeness of occlusion, device migration, delivery system size, 
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and ease of delivery has limited their use [2, 5, 6, 9, 21, 22, 24, 25, 27] and led to the 
development of the Amplatz® Canine Ductal Occluder (ACDO) [1, 33]. The ACDO is 
very successful in PDA closure treatments, yet is still limited by cost and its relatively 
large delivery system profile. While some advances have been made to reduce the profile 
[68], the smallest sheath that current commercial devices can be delivered through is still 
a 4Fr sheath, restricting the size (body weight) range of dogs that can be occluded 
percutaneously.  
A prototype nitinol foam cage (NFC) device that utilizes shape memory polymer 
(SMP) foams has been developed as previously described in Wierzbicki et al [56] with 
design modifications to the shape for improved stability and increased foam capacity. The 
NFC prototype utilizes an SMP polyurethane foam, rather than a dense nitinol mesh to 
occlude flow. SMPs are a unique class of materials that can be heated above a 
characteristic glass transition temperature (Tg) and when deformed and cooled below the 
Tg, hold a secondary shape. The polymer can then be actuated back to its original 
configuration through an entropy driven process by increasing the temperature of the 
polymer above its Tg via an external stimulus such as heat or contact with body 
temperature blood [35]. The unique mechanical and embolic properties of these materials 
have led to the investigation of multiple biomedical embolic device applications for 
endovascular occlusion [39, 40]. Multiple in vitro and in vivo studies have been conducted 
demonstrating the favorable occlusion and biocompatible properties of these materials, as 
shown through occlusion within 2 minutes once implanted [49] and minimal inflammation 
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characterized by dense tissue growth and collagen deposition at 90 days post-implant, 
prompting investigation for their use in other embolization applications [38]. 
 The prototype NFC discussed herein is constructed from one continuous nitinol 
conduit with three sections: the proximal cage, waist, and distal cage, and inclusion of 
SMP foam. In endovascular deliveries, the distal cage is advanced out of the catheter first 
and pulled against the pulmonary artery wall, serving as an anchor point and landmark for 
the device and clinician, respectively. The waist is designed to be oversized relative to the 
minimal ductal diameter (MDD) by approximately 2x, such that it will apply an outward 
force to the ductus, aiding in stability. The proximal cage expands to apply pressure to the 
ampulla wall and is the attachment region for the foam. The SMP foam is anchored within 
the proximal cage and spans and fills all three sections of the frame.  
Through discussions with clinicians, multiple design criteria were defined to 
determine device success. First, the device must be deliverable through a 4 Fr sheath 
having an internal diameter of 1.3 mm or smaller as larger sheaths and catheters cut out a 
large subset of the canine population that can be treated with minimally invasive devices. 
Additionally, the prototype must be retractable into the sheath in the event of an improper 
deployment or sizing, be visible under fluoroscopy following delivery, and remain stable 
once deployed at physiological and elevated pressures. Fabricated NFC prototypes were 
tested against ACDO performance in multiple verification tests to evaluate strut integrity 
and nitinol frame radial forces, as well as stability and deployment characteristics in 
simplified and physiological PDA models, respectively, under experimental flow 
conditions.  
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4.2 Methods 
4.2.1 Device Fabrication 
 NFC prototypes were fabricated in a similar way to those described in Wierzbicki 
et al [56]; however, two variations in wall-thickness were used to assess differences 
regarding the effects of strut stiffness on the prototype’s deployment characteristics. 
Briefly, the NFC prototypes were fabricated by cutting ten equally spaced slots radially 
into a straight nickel titanium alloy (nitinol) tubing using an excimer laser (Resonetics, 
Nashua, NH). The thin-walled prototypes (NFCTn) were constructed using 0.044” outer 
diameter (OD) and 0.041” inner diameter (ID) (NDC, Fremont, CA) tubing (0.0015” wall 
thickness), while the thick-walled prototypes (NFCTk) were constructed using 0.044” OD 
and 0.040” ID (Vascotube, Birkenfeld, Germany) tubing (0.002” wall thickness).0.002” 
wall thickness. One continuous slot was used to form the cage in this design, rather than 
two consecutive slots used previously. The laser cut nitinol tubes were deburred using 
abrasive paper and sonicated in isopropyl alcohol. Custom fixturing compressed the 
tubing, while allowing the struts to expand to the desired shape with a waist of 6 mm OD, 
shown in Figure 4.1. The final shape was defined by annealing the nitinol frame and fixture 
within a furnace held at 550°C for twenty-five minutes, followed by a water quench. A 
threaded release mechanism was laser welded to the proximal end of the device and an 8 
mm OD, 5 mm length SMP foam was compressed to a minimal diameter and epoxied into 
the lumen of the proximal portion of the device. Figure 4.2 illustrates a comparison 
between the ACDO and the NFCTn prototype with a compressed and expanded foam 
insert. Additionally, a subset of thick walled prototypes (NFCTk) were electropolished 
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(NFCTkEP) (Able Electropolishing, Chicago, Il) to a wall thickness of approximately 
0.0015” to evaluate how electropolishing influenced frame durability and fatigue life.  
 
4.2.2 PDA Model Fabrication 
 While the PDA morphology varies from animal to animal, there are three basic 
geometries the ductus arteriosus may manifest that vary in size and shape [7]. Simplified 
thin walled silicone models were fabricated with shapes based on those described by 
Miller et al [7], including the cylindrical (IIA) and elliptical ampulla (IIA ovular), conical 
ampulla (IIB), and a wide ampulla (WA) models with appropriate (3 mm) and oversized 
(5 mm) minimal ductal diameters (MDD) relative to our prototype’s waist diameter 
(Figure 4.3). Dimensions of all simplified models are detailed in Table 4.1. The WA model 
simulates conditions in which the device struts do not contact the ampulla walls, as could 
occur shortly after occlusion [2]. The 6 mm waist of the NFC prototype is designed to be 
twice the diameter of the appropriate PDA MDD. Model MDDs were designed such that 
the prototypes would evaluate 2x and 1.2x oversizing to serve as a safety factor for 
clinician device sizing. Additionally, elliptical morphology dimensions were applied for 
the IIA ovular model to account for irregularly shaped PDAs that occur in vivo (personal 
communication: Sonya Gordon, DVM; Ashley Saunders, DVM).  
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Figure 4.1: Shape setting procedure for NFC prototypes. A: Laser cut nitinol tube. 
Gauge pin placed within lumen across the length of the tube. B: Laser cut tube placed 
within shape setting clamps (top to bottom: proximal, waist, distal) with struts 
expanded to accommodate proximal spacer (top half of clamps not shown. Spacer 
shown sectioned in half). C: Proximal spacer placed within proximal clamp. D: Waist 
clamp butted against proximal clamp. E: Distal clamp butted against waist clamp. 
F: Shape set nitinol cage following heat treatment and removal from the fixture. 
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Figure 4.2: NFC prototype comparison to ACDO. A: ACDO, B: NFC with foam 
compressed, C: NFC with foam expanded. Cage regions defined in left most column. 
 
 
 
 
Figure 4.3: Simplified PDA geometries. Schematics of each simplified thin-walled 
PDA model used in experimental flow stability studies. 
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Table 4.1: Dimensions of simplified thin-walled PDA models used in experimental 
flow stability studies. 
Model Ampulla Diameter 
(mm) 
Minimal Ductal Diameter 
(mm) 
Device Waist 
Oversizing 
IIA 8 3 2x 
 8 5 1.2x 
IIA 
ovular 
6 x 8 3 x 4 ~2x 
IIB 10 3 2x 
10 5 1.2x 
Wide 
Ampulla 
12 3 2x 
12 5 1.2x 
 
 
 
 Flexible, thin-walled polydimethyl siloxane (PDMS) molds of the simplified PDA 
geometries were constructed by 3D printing the vessel lumen using a dissolvable material 
and the outer wall mold pieces using a non-dissolvable material. PDMS resin was injected 
into the mold to form a wall thickness of approximately 0.5 mm and then cured. The 
printed polymer lumen was then dissolved from the PDMS mold in a heated base bath 
solution completing the model.  
 Two rigid PDMS molds were constructed based on reconstructions from computed 
tomographic angiograms (CTA) of the canine PDA. The rigid physiological PDA models 
were made in a similar fashion as described in Wierzbicki et al. as the complex geometry 
complicates flexible, thin-walled mold manufacture. Briefly, the surfaces of the aorta, 
PDA, and, MPA were extracted and sectioned using Mimics (Materialise, Belgium). 
Because the CTAs provided were an unusual morphology, the geometry was minimally 
modified to resemble a the IIA and IIB taper with a 3 mm MDD (Figure 4.4). The extracted 
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volume was then 3D printed with a dissolvable material and the model was cast in PDMS 
in a similar manner to the simplified PDA models.  
 
 
 
 
Figure 4.4: Physiological PDA models used to obtain feedback on deployment 
characteristics. Red dye placed within lumen for visibility of the aorta, ampulla, main 
pulmonary artery (MPA), and minimal ductal diameter (narrowest portion between 
ampulla and MPA). 
 
 
 
4.2.3 Mechanical Verification Tests 
4.2.3.1 Device Fatigue Test 
 A preliminary analysis of fatigue characteristics was conducted by axially cycling 
the nitinol frame on a dynamic mechanical analysis (DMA) unit (DMA Q800, TA 
instruments, New Castle, DE). Three untreated, NFCTn, and three electro-polished, 
NFCTkEP, nitinol frames were cycled with an amplitude of 1 mm at a frequency of 2 Hz 
for approximately one million cycles simulating small deflections that the devices would 
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be subject to in vivo. Untreated samples were prepared as described in Section 2.1 and 
were not electropolished or processed further following shape setting. The force imparted 
by the NFCTn and NFCTkEP devices were recorded and monitored for sudden changes and 
the struts were visually inspected for damage following the test.  
 
4.2.3.2 Radial Force Measurements 
 The radial force exerted by the nitinol frames of the NFCTn and NFCTk and ACDO 
were measured using a Blockwise J-CrimpTM RJA62 Radial Compression Station 
(Blockwise Engineering LLC, Tempe, AZ) attached to an Instron 5965 Test Frame 
(Instron, Norwood, MA) held at 37°C. The Blockwise utilizes a linear relationship 
between the axial force measured by the load cell (F), and the total radial force (TRF), as 
shown in equation (1):  
𝑇𝑅𝐹 = 2.712 ∗ 𝐹     Eq. (4.1) 
where, 2.712 is a conversion constant provided by Blockwise for our instrument. 
Devices were first loaded into a polytetrafluorethylene (PTFE) sheath (1.35 mm 
ID, Cole Parmer, Vernon Hills, Il) and positioned within the bore of the Blockwise for 
delivery. The sheath was then retracted, allowing the devices to expand. Both distal and 
proximal cages contacted the straight tubular bore. The radial force of the NFCTn. NFCTk, 
and ACDO was measured at diameters between 4 and 12 mm within the bare surface bore 
of the Blockwise, denoted STn, STk, and SACDO respectively. Additionally, devices were 
deployed into a 5.5 mm ID, 6.5 mm OD vessel mimic (LifeLike Biotissuue, London, ON) 
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placed within the Blockwise bore to measure the constrictive force required to prevent full 
vessel distension resulting from the nitinol frame, denoted BTn, BTk, and BACDO.  
As the NFC prototypes and ACDO exhibit a very different contact area, strut and 
constrictive force were not directly compared. Therefore, wall tension within the mock 
vessel was calculated to compare mechanical properties of the devices. The NFC radial 
forces (STn, STk) and blockwise radial constrictive forces (BTn, BTk) were divided by the 
ten total struts, to obtain the radial force per strut (sTn, sTk) and constrictive force per strut 
(bTn, bTk), respectively. By measuring these two forces, the wall tension as seen in the 
vessel due to the NFC prototypes can be calculated as,  
𝜏𝑁𝐹𝐶 =
𝒔𝑁𝐹𝐶−𝒃𝑁𝐹𝐶
2𝐿 cos 𝛼
,     Eq (4.2) 
where, τNFC is the wall tension in the vessel imparted by an NFC device (N/mm), sNFC is 
the radial force per strut (N), bNFC is the constrictive force per strut (N) of the NFCTn or 
NFCTk prototypes, and L is the strut length contacting the vessel (mm). Figure 4.5 below 
illustrates the strut isolation and free body diagram for the calculation.  
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Figure 4.5: Illustration of vessel mimic wall tension calculation. A: NFCTk in mock 
vessel. Proximal (bottom) and distal (top) struts seen contacting the vessel wall. B: 
Section of idealized decahedron geometry formed by struts contacting the vessel wall. 
C: Vessel segment looking at only one strut. D: Free body diagram of strut contact 
point to analyze wall tension, τ. 
 
 
 
As the ACDO is a continuous structure and does not have discrete struts, it was 
more appropriate to calculate wall tension as,  
𝜏𝐴𝐶𝐷𝑂 = (𝑃𝑆 − 𝑃𝐵)𝑟,     Eq (4.3) 
where τACDO is the wall tension generated by the ACDO, r is the radius of the bore 
diameter, PS, the contact pressure applied by the ACDO, was calculated as, 
𝑃𝑆 =  
𝑆𝐴𝐶𝐷𝑂
𝑆𝐴𝑐𝑜𝑛𝑡𝑎𝑐𝑡
,    Eq (4.4) 
and PB, the compressive stress applied by the Blockwise to the ACDO within the mock 
vessel, was calculated as, 
𝑃𝐵 =  
𝐵𝐴𝐶𝐷𝑂
𝑆𝐴𝑐𝑜𝑛𝑡𝑎𝑐𝑡
,     Eq (4.5) 
where, SACDO is the radial force (N) applied by the ACDO, and SAcontact is the surface area 
(m2) of the ACDO in contact with the vessel wall, and SAV is the radial force (N) applied 
by the ACDO within the mock vessel. The strut contact length and SAcontact were 
determined from images, similar to the one shown in Figure 4.5A, with Image-J™ 
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software (http://rsb.info.bih.gov/ij/). Three NFCTn and NFCTk were measured, and one 
ACDO were tested, at least three times each at each diameter.  
 
4.2.4 Device Stability Testing Using Simplified in vitro Models 
4.2.4.1 Flow Setup for Simplified in vitro PDA Models 
 A gravity fed flow loop held at approximately 37°C was built to create a pressure 
driven flow to subject the devices to physiological (100 mmHg) and elevated (200 mmHg 
and 300 mmHg, respectively) pressures. A needle valve positioned upstream of the PDA 
model was used to control the pressure gradient applied to the system. Figure 4.6 displays 
a schematic of the flow set up.  
 
 
 
 
Figure 4.6: Schematic of flow loop used in device stability studies. 
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4.2.4.2 Device Preparation and Delivery 
 To provide a worst-case scenario for the NFC device geometry, the NFCTn 
prototypes were used for comparison against the commercial ACDO device, as nitinol 
frames with a wall thickness smaller than of 0.0015” would not be used for this 
application. The NFCTn prototypes were fitted with compressed SMP foams and loaded 
into PTFE introducer tubes. After setting the pressure gradient across the ductus to 100 
mmHg, a 4 Fr sheath (Cook Medical, Bloomington, IN) was passed across the MDD such 
that the tip resided in the modeled pulmonary artery. The introducers containing devices 
were loaded into the sheath and the devices were advanced through the sheath until the 
distal cage was exposed. The delivery cable and sheath were retracted together such that 
the distal cage rested against the pulmonic ostium of the model. The proximal cage was 
then unsheathed. The delivery cable was then pushed forward to allow the proximal cage 
to conform to its cupped shape and to position the foam in the ampulla, MDD and 
pulmonary artery. Prior to release, a push-pull test was performed, in which gentle forward 
and backward motion was applied to the delivery cable to ensure that the device was stable 
and not easily pushed into the pulmonary artery [15]. The SMP foam was allowed to fully 
expand (~2 mins) before releasing the device by unscrewing it from the delivery cable. 
  
4.2.43 Device Stability Tests 
 Three unique NFCTn prototypes and one 6 mm waist ACDO were tested in all 
simplified models three times each. The pressure gradient across the model was set to 100 
mmHg prior to delivery of the devices. Both the NFCTn and ACDO were delivered into 
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the simplified PDA models following the protocol described in 2.4.2. Following device 
deployment, the pressure gradient was readjusted to 100 mmHg, as the pressure across the 
PDA increases following deployment, and held at 100, 200, and 300 mmHg for five 
minutes each consecutively, while images were captured in one minute intervals using a 
digital camcorder (Panasonic HDC-HS80, Newark, NJ). Devices in the all 3 mm and 3x4 
mm MDD models were subjected to all three pressures, but the devices, when implanted 
into the 5 mm MDD models, were only subjected to 100 and 200 mmHg. The flow system 
could not develop a pressure gradient of 300 mmHg with devices (NFC or ACDO) 
deployed, as the devices did not generate a high enough resistance to flow. Following the 
tests, migration/dislocation of the distal tip, relative to the initial deployed position was 
measured using ImageJ™ software.  
 
4.2.5 Deployment Performance in Physiological in vitro Models 
4.2.5.1 Device Preparation and Delivery 
NFC prototypes were fabricated using methods described in Section 2.1. The 
delivery characteristics of 6 mm NFCTn and NFCTk prototypes and a 6 mm ACDO were 
evaluated in the two different rigid PDMS models of a physiologically representative PDA 
as shown in Figure 4.4. Two NFCTn and NFCTk prototypes, and one ACDO were prepared 
and loaded into PTFE introducers. Before delivery, the pressure drop across the ductus 
was set to 120 mmHg, and the flow rate on the pump was constant for the entire test. The 
water in the flow loop was maintained at approximately 37°C. One of each type of NFC 
was deployed by a clinician into each physiological model, in a similar manner to that 
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described in Section 2.4.2 using fluoroscopic guidance. The same ACDO was used in both 
deliveries. Deployment characteristics such as ease of advancement through the catheter, 
deployment, positioning, and retraction were recorded. 
 While the pressure drop across the ductus was set to 120 mmHg, and the flow rate 
on the pump was constant for the entire test, the pressure gauges were not positioned 
immediately proximal and distal to the model ductus. Therefore, the actual pressure drop 
across the PDA may have presented lower than measured. However, the goal of this 
experiment was not to assess stability, as evaluated in Device Stability Testing (see Section 
2.4), but rather to obtain clinician feedback on deployment characteristics and potential 
future improvements. 
 
4.2.5.3 Device Retraction and Repositioning 
 Following deployment and after allowing the foam to fully expand, retraction was 
attempted by advancing the catheter to the proximal struts and pulling on the delivery 
cable and retracting them back into the sheath. Following recapture, the device was 
redeployed by the clinician following the previously described delivery protocol. 
Retraction and redelivery characteristics and clinician recommendations were recorded. 
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4.3 Results and Discussion 
4.3.1 Device Fatigue 
 All six devices withstood the one million cycle fatigue test, assessing strut 
integrity. The NFCTn (n=3) and NFCTkEP (n=3) devices produced a constant load of 0.019 
± 0.001 N and 0.013 ± 0.001 N, respectively, throughout the testing. Sharp decreases in 
the load would have indicated that a strut had completely fractured. There were no grossly 
visible fractured struts, on either the NFCTn or NFCTkEP, indicating that the nitinol frames 
should withstand implantation even with minimal post processing done on the laser cut 
nitinol. The NFCTkEP frames did feel more fragile and soft compared to the untreated 
samples when loading them into the DMA clamps. Additionally, the NFCTkEP samples also 
exhibited lower force during fatigue testing and exhibited permanent elongation following 
fatigue testing, indicating that the treatment could have affected the material’s strength. 
The lower force could also be attributed to the reduced strut width of the NFCTkEP (0.009”) 
compared to the strut width of the NFCTn, (0.011”) [69].  
Figure 4.7A-C shows a comparison of the NFCTk and NFCTkEP, and an NFCTkEP 
positioned within the DMA clamps. Figure 4.7D-F show SEM micrographs of NFCTn , 
NFCTk, and NFCTkEP prototypes post-test. The strut thicknesses of the NFCTn and NFCTk 
prototypes appear much greater than that of NFCTkEP sample due to the recast that formed 
on the edge during laser cutting because of melted nitinol. Additionally, minor defects or 
notches (Figure 4.7F) were present on some struts at the bends in the proximal and distal 
zones, but these were believed to either form during shape setting or as a defect during 
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laser cutting as the notches only on strut edges and were not present throughout the entire 
strut width. Further, defects did not propagate during fatigue tests.  
 
 
 
 
Figure 4.7: A: Untreated thick-walled, NFCTk, prototype. B: Electropolished thick-
walled, NFCTkEP, prototype. C: NFCTkEP prototype loaded into DMA clamps for 
fatigue testing. D: SEM micrograph of untreated NFCTn. E: SEM micrograph of 
NFCTk. F: SEM micrograph of NFCTkEP. 
 
 
 
While optimization to the electropolishing step is still required, it was 
demonstrated that both NFCTk prototypes could be treated with a commercially relevant, 
light electropolish (~0.0006” total material removal) and untreated NFCTn prototypes 
could withstand a short-term fatigue test. Electropolishing is a standard and typically a 
necessary processing technique used on laser cut parts to improve surface finish, corrosion 
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resistance biocompatibility and fatigue life by reducing stress concentrations and heat 
affected zones [70-72]. Formation of recast, debris, and heat affected zones is a known 
issue related to laser cutting nitinol with long pulsed excimer lasers (100 Hz) [73]. 
Therefore, future nitinol frames should be cut using a femtosecond pulsed laser, to reduce 
these effects, in turn reducing standard processing techniques prior to electropolishing [70, 
73].  
This pilot fatigue test provided preliminary evaluation of frame integrity to ensure 
that the device would not fail on a short time scale with the proposed number of struts and 
strut width, which prompts further evaluation of the NFCTn design.  
 
4.3.2 Radial Force Measurements 
 The contact pressure/strut force of the NFCTn, NFCTk, and ACDO device was 
plotted against bore diameter as shown in Figure 4.8A.1-A.3. The strut force of the NFCTk 
was higher than that of the NFCTn at all diameters tested, as expected. Contact 
pressure/strut force was highest for all devices in the smallest bore diameters and tended 
to decrease as the bore diameter increased, allowing the NFC cage diameter to increase, 
until the bore diameter was approximately the same diameter as the original NFC cage 
design. The large standard deviation in some tests is due to variations in handling during 
device deployment. Since the devices are delivered into a straight tube and not into the 
PDA geometry, as they are intended to fit, the cages would sometimes angle, torque, or 
struts would catch on themselves, influencing the measured forces. These effects would 
be minimized during delivery into physiological PDAs due to the different stages and 
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regions of cage deployment and delivery. Local maxima and minima in the curves are due 
to the unique recovery shapes of the multi-cage design expanding at different diameters.  
 
 
 
 
Figure 4.8: Strut force/contact pressure, Blockwise pressure/force and wall tension 
of ACDO, NFCTn, NFCTk devices. A.1-A.3: Contact pressure/strut force of the 
ACDO, NFCTn, NFCTk respectively. B.1-B.3: Blockwise pressure/force and wall 
tension of the ACDO, NFCTn, NFCTk respectively. Three NFCTn and NFCTk and one 
ACDO were tested at least three times each at each Blockwise bore diameter. 
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 The plots in Figure 4.8B.1-B.3 display the compressive force applied by the 
Blockwise blades (BACDO, btn, btk) that prevented device expansion within the vessel mimic 
and the wall tension generated within the vessel wall due to device expansion (SACDO, stn, 
stk). At smaller bore diameters, the Blockwise applies a compressive force, preventing 
device cage expansion, and the wall tension (τACDO, τTn, τTk) is low at smaller bore 
diameters as the Blockwise is taking most the load. However, as the bore diameter 
increases, the strength of the vessel wall matches the radial force imparted by the device 
cage, creating a stress equilibrium between the vessel mimic and device (Figure 4.8B.1-
B.3, starred region). At this point, maximum vessel distension has occurred and the 
Blockwise compressive force approaches zero. While it is difficult to compare strut force 
and contact pressure between the NFCs and ACDO due to differences in geometry, wall 
tension that developed due to device expansion can be compared. Table 4.2 shows the wall 
tension and vessel distension, the difference between the bore diameter at stress 
equilibrium and the vessel OD. The ACDO generated 0.031 ± 0.0007 N/mm of wall 
tension compared to 0.009 ± 0.0007 and 0.012 ± 0.0034 N/mm generated by the NFCTn 
and NFCTk, respectively.  
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Table 4.2: Vessel mimic distension for each device type defined as the difference 
between the bore diameter at equilibrium and the unloaded vessel mimic OD. 
Device Type Wall Tension at 
Stress Equilibrium 
(N/mm) 
Approximate Vessel 
Distension at Stress 
Equilibrium (mm) 
ACDO 0.031 ± 0.0007 3 
NFCTn 0.009 ± 0.0007 1 
NFCTk 0.012 ± 0.0034 1.5 
 
 
 
 
 The distension of both the NFCTn and NFCTk prototypes and ACDO was 
approximately 1, 1.5, and 3 mm, respectively. While the large amount of vessel distention 
in all devices could lead to clinical concerns such as vessel perforation, or pressure 
necrosis, there has not been clinical evidence of such incidence due to oversizing in 
stenting [69] or PDA procedures in literature. While there have not been reported 
incidences of vessel perforation using the ACDO, clinicians have expressed concerns on 
the amount of over sizing in the ampulla in some cases [personal communication, Sonya 
G. Gordon DVM]. However, animal studies have shown that stents can protrude as much 
as 2 mm further than the adventitia and remain covered with connective tissue [69]. 
Overall, the similar deployment characteristics of the NFCTk along with lower distension 
(2x lower) and wall tension (2.5x lower) encourage further investigation. The lower vessel 
distension and reduced wall tension generated by the NFC prototypes indicate that 
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implantations of this device should not result in significant vessel trauma or ampulla 
rupture. 
 It should be noted that the radial force values measured include contributions of 
both the proximal and distal cages representing a worst-case deployment wherein the 
entire device was deployed into a straight tubular, Type III (geometry not shown) PDA 
[7]. In a standard deployment, only the proximal cage and waist apply outward forces to 
the ductus. The distal cage resides along the pulmonary artery wall and therefore should 
not exert an outward force on the vessel. However, it was not possible to replicate this due 
to the straight, cylindrical geometry of the Blockwise, meaning the radial force may be 
slightly overestimated for all devices including the ACDO. 
 
4.3.3 Device Migration in Simplified in vitro Models 
 Migration was measured as movement of the distal tip of the device relative to the 
deployed position for stability evaluation. Qualitative inspection of the images captured 
of the devices deployed into the 3 and 5 mm MDD models (Figures 4.9 and 4.10 
respectively) do not show motion of either the NFCTn or ACDO frames. However, 
measurements of distal tip motion displayed minimal movement of both the NFCTn and 
ACDO. The device migration in the 3 mm MDD models (2x oversized MDD) was lower 
or comparable to the devices deployed into the 5 mm MDD (1.2x) sized models, with 
values shown in Table 4.3. The axial migration of the NFCTn prototype, when compared 
to the ACDO is negligible. The greatest migration occurred at a pressure gradient of 300 
mmHg in the simplified IIA 3mm and WA 3mm models for both the NFCTn and ACDO 
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configurations. Zero migration indicates that either there was no motion seen, or that the 
distal nub retracted towards the minimal ductal diameter. The retraction occurs in response 
to the ampulla widening and allowing the proximal and waist portion of the cage to more 
fully recover to their unconstrained shape.  
Device migration occurred in response to flow passing through and compressing 
the foam into the distal cage, elongating the cage, but not dislodging the frame. Since 
device migration was measured as the axial motion of the distal cage, the foam 
compression could exaggerate skew the migration measurements such that we measure 
the cage elongation and not actual dislocation of the prototype through the anatomy. 
 A secondary result of the foam compression was partial collapse of the proximal 
cage. The drag imparted on the foam that caused elongation of the distal cage also pulled 
the attached proximal nub toward the MDD. Proximal cage collapse was most pronounced 
in the 3 mm IIA and IIB models (Figure 4.9). However, the compression may not be as 
pronounced when implanted in vivo as flow across the device will be negligible following 
foam embolization. Standard delivery practices of the ACDO indicate that the device 
should not be released from the delivery cable until only a minor persistent flow through 
the ductus is present or it is completely occluded [33], thereby minimizing compression 
and migration due to flow. 
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Figure 4.9: Dislocation study for 3 mm MDD simplified models. NFCTn prototypes 
deployed in all 3 mm MDD PDA geometries at increasing pressures (top to bottom). 
Simplified schematic of each model shown in the bottom row. Minor motion of the 
distal tip (pulmonary artery side) is present in all models. Proximal cage collapse is 
apparent at a pressure gradient of 200 mmHg and above.  
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Figure 4.10: Dislocation study for 5 mm MDD simplified models. NFCTn prototypes 
deployed in all 5 mm MDD PDA geometries at increasing pressures (top to bottom). 
Negligible motion of the distal tip is present. Simplified schematic of each model 
shown in the bottom row. Proximal cage compression is not as apparent, as the larger 
MDD afforded less resistance to flow. 
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Table 4.3: NFCTn and ACDO migration in simplified, flexible PDA models. 
 NFCTn Axial Migration (mm) ACDO Axial Migration (mm) 
 100 mmHg 200 mmHg 300 mmHg 100 mmHg 200 mmHg 300 mmHg 
IIA 3mm 0 ± 0.1 0.1 ± 0.1 0.5 ± 0.3 0 ± 0.1 0.06 ± 0.4 0.1 ± 0.3 
IIA 3x4mm 0 ± 0.2 0.1 ± 0.3 0.2 ± 0.4 0 ± 0.1 0.1 ±0.2 0.4 ± 0.1 
IIB 3mm 0 ± 0.7 0.1 ± 0.1 0.1 ± 0.2 0.02 ± 0.03 0.1 ± 0.1 0.1 ± 0.15 
WA 3mm 0 ± 0.1 0.2 ± 0.2 0.6 ± 0.2 0 ± 0.1 0.2 ± 0.3 0.4 ± 0.4 
       
IIA 5mm 0.06 ± 0.1 0 ± 0.3 n/a 0.1 ± 0.2 0 ± 0.2 n/a 
IIB 5mm 0 ± 0.2 0 ± 0.2 n/a 0.1 ± 0.1 0.1 ± 0.2 n/a 
WA 5mm 0.1 ± 0.1 0.2 ± 0.2 n/a 0.031 ± 0.1 0.1 ± 0.2 n/a 
 
 
 
 It is promising that the NFCTn prototypes, even with an oversize factor of only 
1.2x, remained stable at up to twice the physiological pressure, despite clinical 
recommendations for devices be with a waist 2x oversized relative to the MDD. 
Additionally, two-dimensional angiography of the PDA does not always result in an 
accurate MDD measurement and therefore it is important that a safety factor is 
incorporated into the device sizing. Whereas, the simplified models exhibited a rigid 
MDD, the flexible nature of the canine PDA may allow the struts in the waist to more fully 
expand, allowing the device to more closely return to its programmed shape. Greater 
expansion of the waist will result in frame conformance similar to that seen in the 
oversized MDD models, reducing the prototype’s protrusion into the pulmonary artery 
and minimizing the effects of foam compression. While the flexible, thin-walled PDMS 
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models did not allow for extensive MDD dilation, minimal NFC migration in the oversized 
MDD’s demonstrated that the device could withstand a vessel configuration which may 
occur after deployment.  
 Overall, the minimal measured migration of the NFCTn prototypes is comparable 
to that of the ACDO in all models tested at physiological and elevated pressures. The test 
shows that there is a minimal risk of NFC device migration following implantation. 
   
4.3.4 Device Deployment and Retraction in Physiological in vitro Models  
4.3.4.1 Device Deployment and Retraction Characteristics 
 The NFCTk and NFCTn prototypes and ACDO were successfully delivered to both 
IIA and IIB physiological models. The angle at which the models were deployed as well 
as the rigid nature of the model did not allow the proximal cages of any NFC devices or 
the ACDO to return and hold their preformed shape and conform to the ampulla taper as 
expected in the elastic PDA vessel of a dog. Figure 4.11, below shows the deployment 
sequence of an NFCTk deployed into the IIB Model.  
 Retraction was successful in all device types (NFCTn, NFCTk, ACDO) tested. For 
each device, the sheath was positioned against the proximal struts and pulling on the 
delivery cable. For the NFCTn and NFCTk prototypes, retraction was attempted after the 
foam had expanded (~2-5 mins). The force required to retract the NFCTk was comparable 
to that of the ACDO. 
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Figure 4.11: Delivery sequence of NFCTk in physiological IIB model. A: Sheath 
deployed across the MDD. The compressed NFC can be seen within the sheath. B: 
Distal cage deployed. C: Distal cage pulled against pulmonary artery ostium. D: 
Proximal cage deployed and device released. Mask overlayed to emphasize PDA 
morphology.  
 
 
 
4.3.4.1.1 Clinician Feedback on Thin-Walled NFC Device Characteristics 
 The NFCTn was successfully deployed, retracted, and repositioned, and passed a 
light push/pull test performed by a clinician (Sonya G Gordon, DVM). However, there 
were some concerns regarding the tactile feedback during delivery as well as visibility 
under fluoroscopy. First, the NFCTn was more difficult to distinguish under fluoroscopy 
compared to the NFCTk or the ACDO (Figure 4.12). This lack of strut opacity forced the 
clinician to rely mostly on the radiopaque markers located on the proximal and distal tips 
during placement. Secondly, during deployment of the distal cages, clinicians typically 
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feel for a distinct “pop” as the distal cage of the ACDO is advanced out of the cage and 
abruptly expands to its preformed shape. The NFCTn exhibited a slight “pop”, but it was 
much less distinct as compared to the ACDO and NFCTk prototype deployment. 
Additionally, the distal cage of the NFCTn was easily deformed and did not provide a 
noticeable change in resistance to the clinician to indicate that the cage had caught onto 
the pulmonary artery wall. The proximal cage did not return to its programmed cup shape. 
Finally, following delivery of the proximal cage, it was relatively easy to push the frame 
through the ductus. It was noted that this lack of tactile feedback during deployment may 
make the NFCTn prototype delivery too different from the current ACDO, which may delay 
or inhibit device adoption. However, it is believed that these issues are related to the thin 
struts and increasing their thickness and respective stiffness, could improve these qualities. 
 
4.3.4.1.2 Clinician Feedback on Thick-Walled NFC Device Characteristics 
 The NFCTk prototype was successfully deployed, retracted, and repositioned, and 
passed a heavy push/pull test in which the clinician applied much more force than what is 
used in normal canine deliveries. The increased strut wall thickness for NFCTk (0.002”) 
compared to the NFCTn (0.0015”) greatly improved the overall feel and visibility of the 
device under fluoroscopy (Figures 4.12). Further, the NFCTk strut thickness did offer more 
resistance than the NFCTn while advancing through the catheter, but it was still less than 
the ACDO, and was not an issue. The distal cage of the NFCTk exhibited a distinct “pop” 
when it was deployed and offered noticeably higher resistance compared to the NFCTn 
prototype when pulled against the pulmonic ostium of the MDD, indicating to the clinician 
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that it was in proper position and the proximal cage should be unsheathed. Like the NFCTk, 
the proximal cage of the NFCTk did not return to its programmed cupped shape. It was 
noted that this prototype “felt very nice coming out [of the sheath]” meaning that the 
clinician could feel the cages deploy and when they were in proper position. In summary, 
the increased tactile feedback and greater stiffness provided by the NFCTk prototype 
increases its ease of delivery compared to the NFCTn device. 
 
4.3.4.1.3 Clinician Feedback on ACDO Characteristics 
 The ACDO was successfully deployed, retracted, and repositioned in the models. 
It offered the most resistance while advancing through the sheath, even compared to the 
NFCTk. The proximal cage of the ACDO did not return to its preformed shape and looked 
nearly identical to that of the NFCTk. This indicated that all devices (ACDO and NFC) 
were either oversized relative to the ampulla of the model, or more likely, the rigid model 
prevented ampulla distention and expansion, preventing return to their cupped geometries. 
In the future, flexible PDA models using the physiological anatomies should be created to 
more accurately mimic the deployment characteristics. 
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Figure 4.12: Devices deployed into physiological PDA models. A-C: Thin walled 
(NFCTn) NFC (still attached to delivery cable), thick walled (NFCTk) NFC, and 
ACDO (left to right) deployed into the IIA physiological model, respectively. D-F: 
NFCTn, NFCTk, and ACDO (left to right) fully deployed into the IIB physiological 
model, respectively. 
 
 
 
4.5 Conclusions 
 While the ACDO is effective at treating canine PDA, it’s large delivery system 
profile can be limiting when treating smaller dogs with narrow vasculature. The dense 
nitinol mesh of the ACDO is used for both stability and occlusion, whereas in the NFC 
nitinol is used for stability and an SMP foam is used for occlusion. The reduction in 
materials of the NFC prototypes has multiple benefits including improvement in ease of 
delivery by reducing both the force required to advance the device through the catheter 
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and having an equivalent force required to retract the device into the sheath, and 
potentially reducing the cost of production.  
 The NFC prototypes conformed to all design criteria. An interesting aspect of this 
design is the scalable nature of the prototype. Like the previous version of the prototype, 
the frame is scalable in that by changing the length of the laser cut struts, the diameter of 
the cages can be increased or decreased. As the delivery profile of the NFC is determined 
by the OD of the nitinol tube and compressed SMP foam, we predict that larger waist 
diameter NFCs can be delivered into smaller catheters and sheaths compared to 
comparable waist ACDOs. Additionally, by reducing the OD of the nitinol tubing used to 
create the frame, NFCs with a waist of 4 mm and smaller may be able to be delivered 
through a 4 Fr catheter (~1 mm ID). Figure 4.13 shows conceptual 4 mm and 8 mm waist 
NFC devices alongside the tested 6 mm waist NFC prototype. 
 
 
 
 
Figure 4.13: NFC device sizes compared to 6 mm ACDO. Left to right: 6 mm ACDO, 
4 mm NFC (0.035” OD x 0.031” ID tubing), 6 mm NFC (0.044” OD x 0.040” ID 
tubing), 8 mm NFC (0.044” OD x 0.040” ID tubing). 
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 Based on the supporting stability and deployment results for the NFC devices, we 
plan to pursue the NFCTk design in future studies due to the positive clinician feedback to 
its performance and familiar feel. The increased strut thickness should not negatively 
impact device stability or increase migration, and may improve these aspects by further 
resisting compression. With these changes to the strut thickness, and the positive results 
from the presented studies, including acute strut integrity, lower generated wall tension, 
minimal device migration, and positive clinician feedback, it is believed that the NFC 
could be used to treat canine PDA. 
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CHAPTER V 
CONCLUSIONS 
 
5.1 Summary 
A shape memory polymer based nitinol foam cage (NFC) patent ductus arteriosus 
occlusion prototype device was designed, developed, and tested. The prototypes 
developed in this dissertation serve as a platform for the further development of a shape 
memory polymer based patent ductus arteriosus occlusion device. Both iterations of the 
prototype adhered to the design requirements: were deliverable and retractable into a 4 Fr 
sheath, were stable at physiological and elevated pressures, employed a simple 
detachment, and were visible under fluoroscopy. 
A first generation NFC was constructed using a monolithic nitinol frame with two 
distinct cages and an SMP foam in the proximal cage. The prototype performed acceptably 
and conformed to the defined design requirements in the removal force, radial pressure, 
and in vitro stability tests. While successful, it was determined from these tests that device 
migration could be further reduced with nitinol frame refinement.  
After compiling input from the clinician as well as investigating different 
configurations, a second generation NFC was developed which addressed the above 
limitations. Stability was improved to approximately match that seen with the ACDO by 
using a single nitinol cage with three distinct portions to better conform to the PDA 
anatomy. Additionally, the single, continuous cage gave the frame a propensity to 
compress around the MDD, similar to the mechanism of the ACDO, reducing the 
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possibility of dislocation. The second generation NFC prototypes conformed to the set 
design requirements and performed comparably to the ACDO in the radial force and 
stability tests. Expansion of the NFC produced lower wall tension at stress equilibrium in 
the vessel mimic compared to the ACDO, indicating that the NFC minimizes the risk of 
ampulla rupture or significant vessel trauma upon implantation of the device.  
A unique feature of this design is the scalable nature of the prototype. The nitinol 
frame of both, first and second generation NFC prototypes can be scaled up or down to fit 
different sized PDAs by increasing or decreasing the length of the laser cut nitinol struts 
and shape set with different fixturing. Additionally, larger or smaller SMP foam cylinders 
can be placed within the frame, and the pore size and composition can be specifically 
tailored to allow for reduced compressed diameters or tailored actuation times. The 
compressed diameter of the NFC is only limited by either the outer diameter of the nitinol 
tube or compressed diameter of the SMP foam. Due to the reasons listed, we believe that 
small waist diameter (4 mm and smaller) NFCs can be made deliverable through 4Fr 
catheters (<1 mm ID) and larger devices can be delivered through smaller sheaths 
compared to the ACDO.  
A series of polyacrylamide hydrogel-clotted SMP foams were fabricated and their 
modulus was measured in attempt to match that of blood-clotted small and large pore 
foams. Hydrogel-clotted foams with a modulus that most closely matched that of the 
blood-clotted foams were used in a verification test to demonstrate the utility of these 
materials. The dislocation force of the NFC was measured in multiple PDA geometries 
using bare foam and hydrogel-clotted foams and compared to the ACDO. While there was 
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minimal difference in the dislocation force between bare and hydrogel-clotted foams due 
to foam location within the nitinol frame, the low dislocation force of the NFC suggested 
that a stiffer device may be desired for ease of positioning. This hydrogel clot mimic 
developed serves as a useful tool in benchtop studies for future experiments. Currently, 
most device performance on the benchtop is performed using bare foams. However, this 
metric only estimates acute performance during delivery and shortly after deployment. 
Stability tests can and have been performed in this configuration, but the devices may 
perform differently clotted and in the past, the only way to measure these properties has 
been using actual blood clots or in in vivo studies. The utility of these materials is 
especially present in the testing of peripheral, PDA, and other high flow vessel occlusion 
indications to test a device’s occlusion efficacy and ability to restore flow and pressures 
to surrounding vasculature.  
 
5.2 Challenges and Future Directions 
The goal of this project was to develop a prototype that was ready to be evaluated 
in an animal study and eventually commercialized. However, while many performance 
aspects were solved and evaluated in this work, additional testing is required prior to an 
in vivo study, including: nitinol tubing thickness optimization, laser cutting improvements, 
nitinol passivation, and corrosion testing. 
First, thin wall walled (0.0015” wall thickness) devices were used for most of this 
work and they performed acceptably in all our verification tests, however it was indicated 
in our physiological deliveries that the thick walled (0.002” wall thickness) prototypes 
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exhibited a better feel and stability during deployment. As such, further testing involving 
these thicker walled devices needs to be investigated, including determining whether the 
struts of the thicker walled devices can still be shaped into the tight radius forms of the 
desired geometry, and ensuring that stability at physiological pressures is not impacted. 
The prototypes evaluated in this work were fabricated in house using an excimer 
laser, due to expense and ability to rapidly iterate on the design. However, the excimer 
laser wavelength and pulse width are not optimized for cutting nitinol as these conditions 
tend to result in heat affected zones and recast around the cut edge, increasing the amount 
of post-processing required to improve the finish. Future devices should be fabricated 
using a femtosecond pulsed IR laser. The short pulses result in an athermal process which 
minimizes recast and heat affected zones, reducing the amount of post-processing required 
to prepare an implant grade finish device. It is believed that the light electropolish used in 
Chapter IV on femtosecond laser cut nitinol would result in an acceptable finish for 
implantation.  
Laser cut nitinol devices must be passivated prior to implantation to reduce the 
amount of nickel on the surface of the material. This is typically done through 
electropolishing, a process that removes material from the surface and leaves a passive 
titanium dioxide surface layer improving biocompatibility and corrosion resistance. 
Because our devices form a complex geometry, multiple iterations of electropolish 
parameters may be necessary to ensure consistent and repeatable material removal across 
the entire device frame. Corrosion testing of the electropolished samples will need to be 
conducted to ensure that the treatment adequately passivated the surface.  
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Finally, 6 mm waist devices were the focus of the studies discussed within this 
work. Since PDAs come in wide range of sizes, different sized cages will need to be 
fabricated and tested. Currently, 4mm and 8mm waist devices have been prototyped, but 
more thorough testing of these sizes is required to ensure satisfactory performance. 
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